https://trial.medpath.com/news/vibegron-shows-sustained-long-term-safety-and-efficacy-for-men-with-oab-and-bph 2025-05-02T01:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vibegron-shows-sustained-long-term-safety-and-efficacy-for-men-with-oab-and-bph 2025-05-02T01:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nucleus-pulposus-allograft-shows-promise-for-chronic-back-pain-treatment 2025-05-02T01:40:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nucleus-pulposus-allograft-shows-promise-for-chronic-back-pain-treatment 2025-05-02T01:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ocumet-beacon-a-novel-non-invasive-retinal-imaging-device 2025-05-02T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ocumet-beacon-a-novel-non-invasive-retinal-imaging-device 2025-05-02T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-licenses-discovery-platforms-to-dcx-biotherapeutics-in-strategic-refocus-on-clinical-pipeline 2025-05-02T01:39:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repare-therapeutics-licenses-discovery-platforms-to-dcx-biotherapeutics-in-strategic-refocus-on-clinical-pipeline 2025-05-02T01:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/bluenalu-expands-partnership-with-nomadfoods-to-commercialise-cell-based-products-in-uk-europe 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluenalu-expands-partnership-with-nomadfoods-to-commercialise-cell-based-products-in-uk-europe 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-shows-promising-results-in-children-with-rare-immune-disorder-lad-i 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-shows-promising-results-in-children-with-rare-immune-disorder-lad-i 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-azd0780-cholesterol-lowering-drug-through-phase-ii-and-iii-clinical-trials 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-azd0780-cholesterol-lowering-drug-through-phase-ii-and-iii-clinical-trials 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-antiplatelet-therapy-shows-superior-safety-profile-over-dual-therapy-after-tavr 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-antiplatelet-therapy-shows-superior-safety-profile-over-dual-therapy-after-tavr 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alk-and-ars-pharma-partner-to-co-promote-neffy-first-needle-free-epinephrine-nasal-spray-for-anaphylaxis 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alk-and-ars-pharma-partner-to-co-promote-neffy-first-needle-free-epinephrine-nasal-spray-for-anaphylaxis 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-launches-phase-2-trial-of-mirivadelgat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-launches-phase-2-trial-of-mirivadelgat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-combination-mrna-vaccine-for-covid-19-and-influenza-shows-promise-in-phase-3-trial 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-combination-mrna-vaccine-for-covid-19-and-influenza-shows-promise-in-phase-3-trial 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-sustained-lung-function-improvements-in-copd-patients-with-type-2-inflammation 2025-05-01T23:00:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-sustained-lung-function-improvements-in-copd-patients-with-type-2-inflammation 2025-05-01T23:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/strides-pharma-secures-usfda-approval-for-celecoxib-capsules-targeting-116m-market 2025-05-01T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strides-pharma-secures-usfda-approval-for-celecoxib-capsules-targeting-116m-market 2025-05-01T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/new-bone-marrow-test-could-double-survival-rates-for-acute-myeloid-leukemia-patients 2025-05-01T20:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-bone-marrow-test-could-double-survival-rates-for-acute-myeloid-leukemia-patients 2025-05-01T20:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/cnd-life-sciences-secures-13-5m-series-a-funding-to-advance-skin-based-neurodegenerative-disease-diagnostics 2025-05-01T20:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnd-life-sciences-secures-13-5m-series-a-funding-to-advance-skin-based-neurodegenerative-disease-diagnostics 2025-05-01T20:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-advances-liver-cancer-treatment-with-first-in-human-trial-of-novel-targeted-alpha-therapy 2025-05-01T20:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-advances-liver-cancer-treatment-with-first-in-human-trial-of-novel-targeted-alpha-therapy 2025-05-01T20:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/magnetic-silk-microparticles-a-breakthrough-for-targeted-drug-delivery 2025-05-01T19:36:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnetic-silk-microparticles-a-breakthrough-for-targeted-drug-delivery 2025-05-01T19:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-considers-new-conditional-approval-pathway-for-rare-disease-treatments 2025-05-01T19:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-considers-new-conditional-approval-pathway-for-rare-disease-treatments 2025-05-01T19:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-element-science-s-jewel-patch-a-revolutionary-wearable-defibrillator-for-sudden-cardiac-arrest-risk 2025-05-01T19:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-element-science-s-jewel-patch-a-revolutionary-wearable-defibrillator-for-sudden-cardiac-arrest-risk 2025-05-01T19:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-and-nih-launch-generation-gold-standard-universal-vaccine-platform-to-combat-pandemic-threats 2025-05-01T19:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-and-nih-launch-generation-gold-standard-universal-vaccine-platform-to-combat-pandemic-threats 2025-05-01T19:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/who-set-to-endorse-glp-1-weight-loss-drugs-globally-addressing-access-challenges 2025-05-01T16:41:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-set-to-endorse-glp-1-weight-loss-drugs-globally-addressing-access-challenges 2025-05-01T16:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-and-ovation-io-launch-groundbreaking-glp-1-dataset-to-transform-metabolic-disease-treatment 2025-05-01T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-and-ovation-io-launch-groundbreaking-glp-1-dataset-to-transform-metabolic-disease-treatment 2025-05-01T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-dimerix-lands-940m-licensing-deal-for-kidney-drug-sales-afr 2025-05-01T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-dimerix-lands-940m-licensing-deal-for-kidney-drug-sales-afr 2025-05-01T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/qps-india-successfully-completes-us-fda-regulatory-inspection-marking-46th-regulatory-approval 2025-05-01T16:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qps-india-successfully-completes-us-fda-regulatory-inspection-marking-46th-regulatory-approval 2025-05-01T16:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-tavr-therapy-for-asymptomatic-severe-aortic-stenosis-patients 2025-05-01T16:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-tavr-therapy-for-asymptomatic-severe-aortic-stenosis-patients 2025-05-01T16:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-tarlatamab-shows-promise-in-relapsed-small-cell-lung-cancer 2025-05-01T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-tarlatamab-shows-promise-in-relapsed-small-cell-lung-cancer 2025-05-01T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/armata-s-bacteriophage-therapy-shows-promising-results-in-treating-staphylococcus-aureus-bacteremia 2025-05-01T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armata-s-bacteriophage-therapy-shows-promising-results-in-treating-staphylococcus-aureus-bacteremia 2025-05-01T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/us-biotech-companies-shift-clinical-trials-abroad-amid-fda-uncertainty 2025-05-01T16:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-biotech-companies-shift-clinical-trials-abroad-amid-fda-uncertainty 2025-05-01T16:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-launches-time-precision-network-to-accelerate-phase-i-clinical-trial-enrollment 2025-05-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-launches-time-precision-network-to-accelerate-phase-i-clinical-trial-enrollment 2025-05-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-cimerli-first-interchangeable-biosimilar-for-ocular-conditions-now-available 2025-05-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-cimerli-first-interchangeable-biosimilar-for-ocular-conditions-now-available 2025-05-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amicus-therapeutics-reports-15-revenue-growth-in-q1-2025-expands-portfolio-with-dmx-200-licensing-deal 2025-05-01T14:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amicus-therapeutics-reports-15-revenue-growth-in-q1-2025-expands-portfolio-with-dmx-200-licensing-deal 2025-05-01T14:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/aviadobio-completes-second-cohort-in-phase-1-2-trial-for-frontotemporal-dementia-gene-therapy 2025-05-01T13:59:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aviadobio-completes-second-cohort-in-phase-1-2-trial-for-frontotemporal-dementia-gene-therapy 2025-05-01T13:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/biosplice-initiates-phase-2-trial-of-cirtuvivint-for-advanced-soft-tissue-sarcomas 2025-05-01T13:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosplice-initiates-phase-2-trial-of-cirtuvivint-for-advanced-soft-tissue-sarcomas 2025-05-01T13:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-positive-opinion-for-orphan-drug-designation-to-nuformix-s-nxp002-for-idiopathic-pulmonary-fibrosis 2025-05-01T10:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-positive-opinion-for-orphan-drug-designation-to-nuformix-s-nxp002-for-idiopathic-pulmonary-fibrosis 2025-05-01T10:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/bimekizumab-demonstrates-sustained-three-year-efficacy-in-psoriatic-arthritis-and-axial-spondyloarthritis 2025-05-01T09:54:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimekizumab-demonstrates-sustained-three-year-efficacy-in-psoriatic-arthritis-and-axial-spondyloarthritis 2025-05-01T09:54:49+00:00 hourly 0.9 https://trial.medpath.com/news/statins-linked-to-61-reduced-cancer-mortality-in-cll-sll-patients-on-targeted-therapy 2025-05-01T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/statins-linked-to-61-reduced-cancer-mortality-in-cll-sll-patients-on-targeted-therapy 2025-05-01T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-to-present-new-izervay-data-on-geographic-atrophy-at-major-ophthalmology-congresses 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-to-present-new-izervay-data-on-geographic-atrophy-at-major-ophthalmology-congresses 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/osstec-secures-ps2-5m-to-advance-3d-printed-joint-replacement-technology-to-us-market 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osstec-secures-ps2-5m-to-advance-3d-printed-joint-replacement-technology-to-us-market 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/adela-s-tissue-agnostic-mrd-test-shows-promise-for-predicting-immunotherapy-response-in-solid-tumors 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adela-s-tissue-agnostic-mrd-test-shows-promise-for-predicting-immunotherapy-response-in-solid-tumors 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-acquires-two-biotech-companies-in-strategic-consolidation-move 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concentra-biosciences-acquires-two-biotech-companies-in-strategic-consolidation-move 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/kennedy-mandates-placebo-testing-for-all-new-vaccines-potentially-impacting-fall-covid-boosters 2025-05-01T08:03:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kennedy-mandates-placebo-testing-for-all-new-vaccines-potentially-impacting-fall-covid-boosters 2025-05-01T08:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-favorable-muscle-composition-changes-in-type-2-diabetes-patients-surpass-3-trial-analysis-reveals 2025-05-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-favorable-muscle-composition-changes-in-type-2-diabetes-patients-surpass-3-trial-analysis-reveals 2025-05-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/common-cytomegalovirus-may-enhance-immunotherapy-outcomes-in-melanoma-patients-oxford-study-finds 2025-05-01T05:41:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/common-cytomegalovirus-may-enhance-immunotherapy-outcomes-in-melanoma-patients-oxford-study-finds 2025-05-01T05:41:02+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-to-showcase-advanced-aav-manufacturing-platform-at-asgct-annual-meeting 2025-05-01T05:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexeo-therapeutics-to-showcase-advanced-aav-manufacturing-platform-at-asgct-annual-meeting 2025-05-01T05:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/sapience-therapeutics-to-present-phase-2-lucicebtide-data-for-glioblastoma-at-asco-2025 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sapience-therapeutics-to-present-phase-2-lucicebtide-data-for-glioblastoma-at-asco-2025 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/haleon-partners-with-brightseed-to-leverage-ai-for-natural-bioactive-discovery-in-consumer-health 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haleon-partners-with-brightseed-to-leverage-ai-for-natural-bioactive-discovery-in-consumer-health 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-health-care-deepens-integration-of-atropos-health-s-real-world-evidence-platform-into-clinical-workflow 2025-05-01T04:37:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-health-care-deepens-integration-of-atropos-health-s-real-world-evidence-platform-into-clinical-workflow 2025-05-01T04:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-demands-response-on-alleged-illegal-clinical-trials-at-gujarat-hospital 2025-05-01T04:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-demands-response-on-alleged-illegal-clinical-trials-at-gujarat-hospital 2025-05-01T04:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-deupirfenidone-shows-unprecedented-efficacy-in-ipf-treatment-phase-2b-results-to-be-presented-at-ats-conference 2025-05-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-s-deupirfenidone-shows-unprecedented-efficacy-in-ipf-treatment-phase-2b-results-to-be-presented-at-ats-conference 2025-05-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-biomarker-status-drives-survival-and-cost-disparities-in-advanced-nsclc 2025-05-01T03:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-biomarker-status-drives-survival-and-cost-disparities-in-advanced-nsclc 2025-05-01T03:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-long-term-organ-damage-in-children-following-covid-19-infection 2025-05-01T03:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-long-term-organ-damage-in-children-following-covid-19-infection 2025-05-01T03:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/pl-bioscience-develops-world-s-first-artificial-human-platelet-lysate-for-cell-culture-applications 2025-05-01T03:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pl-bioscience-develops-world-s-first-artificial-human-platelet-lysate-for-cell-culture-applications 2025-05-01T03:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-vaccines-emerge-as-promising-frontier-in-oncology-with-multiple-approaches-showing-clinical-success 2025-05-01T02:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-vaccines-emerge-as-promising-frontier-in-oncology-with-multiple-approaches-showing-clinical-success 2025-05-01T02:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/cml-treatment-market-poised-for-significant-growth-through-2032-amid-wave-of-recent-fda-approvals 2025-05-01T01:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cml-treatment-market-poised-for-significant-growth-through-2032-amid-wave-of-recent-fda-approvals 2025-05-01T01:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/elite-pharmaceuticals-launches-generic-percocet-for-moderate-to-severe-pain-management 2025-05-01T01:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elite-pharmaceuticals-launches-generic-percocet-for-moderate-to-severe-pain-management 2025-05-01T01:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/s-e-bio-secures-landmark-approval-for-first-exosome-based-stroke-therapy-trial-in-korea 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/s-e-bio-secures-landmark-approval-for-first-exosome-based-stroke-therapy-trial-in-korea 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-baxdrostat-in-phase-iii-trials-for-uncontrolled-and-resistant-hypertension 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-baxdrostat-in-phase-iii-trials-for-uncontrolled-and-resistant-hypertension 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-bristol-myers-squibb-achieve-major-milestone-in-molecular-glue-degrader-collaboration-triggering-75m-payment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-and-bristol-myers-squibb-achieve-major-milestone-in-molecular-glue-degrader-collaboration-triggering-75m-payment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enara-bio-strengthens-leadership-team-with-key-appointments-as-company-advances-dark-antigen-t-cell-engager-pipeline 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enara-bio-strengthens-leadership-team-with-key-appointments-as-company-advances-dark-antigen-t-cell-engager-pipeline 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-expands-virtual-clinical-trial-partnership-with-science-37-to-cut-r-d-costs 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-expands-virtual-clinical-trial-partnership-with-science-37-to-cut-r-d-costs 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-two-novel-obesity-treatments-in-phase-iib-trials 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-two-novel-obesity-treatments-in-phase-iib-trials 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/belfast-based-amply-discovery-secures-1-75m-to-accelerate-ai-driven-drug-development-for-cancer-and-antimicrobial-resistance 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belfast-based-amply-discovery-secures-1-75m-to-accelerate-ai-driven-drug-development-for-cancer-and-antimicrobial-resistance 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-appoints-mark-f-kubik-to-lead-oncology-business-development-for-novel-adc-platform 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-appoints-mark-f-kubik-to-lead-oncology-business-development-for-novel-adc-platform 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-initiates-phase-i-studies-of-azd2389-for-liver-fibrosis-and-nash-treatment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-initiates-phase-i-studies-of-azd2389-for-liver-fibrosis-and-nash-treatment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-shows-promise-in-treating-mash-a-serious-liver-disease 2025-04-30T23:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-shows-promise-in-treating-mash-a-serious-liver-disease 2025-04-30T23:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-loba-biotech-as-new-manufacturing-site-for-pegasys-restoring-european-supply 2025-04-30T22:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-loba-biotech-as-new-manufacturing-site-for-pegasys-restoring-european-supply 2025-04-30T22:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-updates-breast-cancer-and-ovarian-cancer-treatment-guidelines-with-new-maintenance-therapy-and-immunotherapy-recommendations 2025-04-30T21:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-updates-breast-cancer-and-ovarian-cancer-treatment-guidelines-with-new-maintenance-therapy-and-immunotherapy-recommendations 2025-04-30T21:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-zejula-shows-promising-results-in-phase-ii-mesothelioma-trial-with-27-reduction-in-disease-progression 2025-04-30T19:37:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-zejula-shows-promising-results-in-phase-ii-mesothelioma-trial-with-27-reduction-in-disease-progression 2025-04-30T19:37:35+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-appoints-biotech-veteran-rahul-kakkar-as-ceo-of-somatic-genomics-company-quotient-therapeutics 2025-04-30T19:37:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-appoints-biotech-veteran-rahul-kakkar-as-ceo-of-somatic-genomics-company-quotient-therapeutics 2025-04-30T19:37:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-astrazeneca-s-imfinzi-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-04-30T17:37:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-astrazeneca-s-imfinzi-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-04-30T17:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-regulus-therapeutics-for-800m-expanding-kidney-disease-portfolio 2025-04-30T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-acquires-regulus-therapeutics-for-800m-expanding-kidney-disease-portfolio 2025-04-30T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-advances-gedeptin-gene-therapy-for-solid-tumors-with-expanded-patent-portfolio-and-promising-clinical-data 2025-04-30T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-advances-gedeptin-gene-therapy-for-solid-tumors-with-expanded-patent-portfolio-and-promising-clinical-data 2025-04-30T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/er-kim-and-puma-biotechnology-partner-to-bring-nerlynx-to-eastern-europe-and-central-asia-for-her2-positive-breast-cancer-patients 2025-04-30T16:38:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/er-kim-and-puma-biotechnology-partner-to-bring-nerlynx-to-eastern-europe-and-central-asia-for-her2-positive-breast-cancer-patients 2025-04-30T16:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/predicta-biosciences-launches-genopredicta-a-novel-diagnostic-test-for-multiple-myeloma 2025-04-30T16:38:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predicta-biosciences-launches-genopredicta-a-novel-diagnostic-test-for-multiple-myeloma 2025-04-30T16:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/cytophage-launches-european-pilot-study-for-aviphage-targeting-antibiotic-free-poultry-production 2025-04-30T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytophage-launches-european-pilot-study-for-aviphage-targeting-antibiotic-free-poultry-production 2025-04-30T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/3p-innovation-launches-next-generation-dpi-filling-technology-promising-faster-production-of-inhalable-therapeutics 2025-04-30T16:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3p-innovation-launches-next-generation-dpi-filling-technology-promising-faster-production-of-inhalable-therapeutics 2025-04-30T16:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/miniject-shows-sustained-5-year-efficacy-in-glaucoma-treatment-istar-medical-reports 2025-04-30T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miniject-shows-sustained-5-year-efficacy-in-glaucoma-treatment-istar-medical-reports 2025-04-30T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/cessatech-s-ct001-nasal-spray-achieves-primary-endpoints-in-pivotal-pediatric-pain-study 2025-04-30T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cessatech-s-ct001-nasal-spray-achieves-primary-endpoints-in-pivotal-pediatric-pain-study 2025-04-30T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-secures-5-million-in-funding-to-advance-commercialization-of-novel-antibiotic-orlynvah 2025-04-30T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-secures-5-million-in-funding-to-advance-commercialization-of-novel-antibiotic-orlynvah 2025-04-30T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/histone-modifications-drive-tumor-associated-macrophage-polarization-in-cancer-immunotherapy 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histone-modifications-drive-tumor-associated-macrophage-polarization-in-cancer-immunotherapy 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/metagenomic-next-generation-sequencing-demonstrates-superior-diagnostic-performance-for-severe-pneumonia-pathogen-detection 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metagenomic-next-generation-sequencing-demonstrates-superior-diagnostic-performance-for-severe-pneumonia-pathogen-detection 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-concedes-defeat-in-covid-19-vaccine-patent-dispute-with-pfizer-and-biontech 2025-04-30T15:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-concedes-defeat-in-covid-19-vaccine-patent-dispute-with-pfizer-and-biontech 2025-04-30T15:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/pangia-biotech-to-present-ai-driven-urine-based-prostate-cancer-detection-platform-at-asco-2025 2025-04-30T15:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pangia-biotech-to-present-ai-driven-urine-based-prostate-cancer-detection-platform-at-asco-2025 2025-04-30T15:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/big-pharma-m-a-activity-surges-as-companies-target-undervalued-biotechs-amid-market-recovery 2025-04-30T14:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/big-pharma-m-a-activity-surges-as-companies-target-undervalued-biotechs-amid-market-recovery 2025-04-30T14:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharma-shares-surge-following-usfda-clearance-of-panelav-oncology-facility 2025-04-30T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharma-shares-surge-following-usfda-clearance-of-panelav-oncology-facility 2025-04-30T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitor-comparison-reveals-optimized-treatment-strategies-for-myelofibrosis-patients-with-cytopenias 2025-04-30T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitor-comparison-reveals-optimized-treatment-strategies-for-myelofibrosis-patients-with-cytopenias 2025-04-30T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-and-boehringer-ingelheim-partner-on-ai-powered-platform-to-transform-ophthalmic-research-and-personalized-eye-care 2025-04-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-and-boehringer-ingelheim-partner-on-ai-powered-platform-to-transform-ophthalmic-research-and-personalized-eye-care 2025-04-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-advances-novel-muscarinic-m4-agonist-to-phase-3-trials-for-schizophrenia 2025-04-30T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-advances-novel-muscarinic-m4-agonist-to-phase-3-trials-for-schizophrenia 2025-04-30T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-approves-velsipity-r-for-moderately-to-severely-active-ulcerative-colitis 2025-04-30T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-approves-velsipity-r-for-moderately-to-severely-active-ulcerative-colitis 2025-04-30T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/honorhealth-launches-first-global-trial-of-novel-t-cell-therapy-targeting-aggressive-melanoma 2025-04-30T13:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/honorhealth-launches-first-global-trial-of-novel-t-cell-therapy-targeting-aggressive-melanoma 2025-04-30T13:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/oncocyte-advances-toward-clinical-trial-for-organ-transplant-rejection-test-kit 2025-04-30T13:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncocyte-advances-toward-clinical-trial-for-organ-transplant-rejection-test-kit 2025-04-30T13:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-files-for-fda-approval-of-cytisinicline-first-new-smoking-cessation-drug-in-nearly-20-years 2025-04-30T11:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-life-sciences-files-for-fda-approval-of-cytisinicline-first-new-smoking-cessation-drug-in-nearly-20-years 2025-04-30T11:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/rage-inhibitor-pipeline-shows-promise-for-inflammatory-diseases-with-5-companies-advancing-novel-therapeutics 2025-04-30T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rage-inhibitor-pipeline-shows-promise-for-inflammatory-diseases-with-5-companies-advancing-novel-therapeutics 2025-04-30T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/x-chem-and-orion-pharma-expand-collaboration-to-accelerate-small-molecule-drug-discovery 2025-04-30T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x-chem-and-orion-pharma-expand-collaboration-to-accelerate-small-molecule-drug-discovery 2025-04-30T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bold-therapeutics-presents-breakthrough-data-on-bold-100-s-neuroprotective-effects-at-aacr-2025 2025-04-30T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bold-therapeutics-presents-breakthrough-data-on-bold-100-s-neuroprotective-effects-at-aacr-2025 2025-04-30T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-alzheimer-s-radiodiagnostic-mk-6240-achieves-pivotal-study-success-nda-filing-planned 2025-04-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-alzheimer-s-radiodiagnostic-mk-6240-achieves-pivotal-study-success-nda-filing-planned 2025-04-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/parp-inhibitor-niraparib-shows-breakthrough-results-in-mesothelioma-treatment 2025-04-30T07:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parp-inhibitor-niraparib-shows-breakthrough-results-in-mesothelioma-treatment 2025-04-30T07:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-first-100-days-tariffs-and-workforce-cuts-reshape-healthcare-industry 2025-04-30T07:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-first-100-days-tariffs-and-workforce-cuts-reshape-healthcare-industry 2025-04-30T07:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/apertura-gene-therapy-partners-with-rett-syndrome-research-trust-to-advance-blood-brain-barrier-crossing-gene-therapy-platform 2025-04-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apertura-gene-therapy-partners-with-rett-syndrome-research-trust-to-advance-blood-brain-barrier-crossing-gene-therapy-platform 2025-04-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/sapient-launches-dynamiq-next-generation-multi-omics-platform-set-to-transform-drug-discovery-and-development 2025-04-30T07:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sapient-launches-dynamiq-next-generation-multi-omics-platform-set-to-transform-drug-discovery-and-development 2025-04-30T07:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/nodthera-s-nlrp3-inhibitor-nt-0796-shows-enhanced-weight-loss-when-combined-with-glp-1-therapy 2025-04-30T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nodthera-s-nlrp3-inhibitor-nt-0796-shows-enhanced-weight-loss-when-combined-with-glp-1-therapy 2025-04-30T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-dismisses-sanofi-s-appeal-orders-amgen-s-repatha-patent-applications-to-proceed-in-australia 2025-04-30T06:00:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-dismisses-sanofi-s-appeal-orders-amgen-s-repatha-patent-applications-to-proceed-in-australia 2025-04-30T06:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/genincode-faces-fda-hurdles-in-de-novo-submission-for-cardiovascular-genetic-risk-assessment 2025-04-30T06:00:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genincode-faces-fda-hurdles-in-de-novo-submission-for-cardiovascular-genetic-risk-assessment 2025-04-30T06:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-path-for-ingenium-s-nk-cell-therapy-gengleucel-to-enter-phase-2-trials-for-mrd-aml 2025-04-30T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-path-for-ingenium-s-nk-cell-therapy-gengleucel-to-enter-phase-2-trials-for-mrd-aml 2025-04-30T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-life-sciences-secures-22-million-private-placement-to-advance-oncology-drug-delivery-platform 2025-04-30T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trisalus-life-sciences-secures-22-million-private-placement-to-advance-oncology-drug-delivery-platform 2025-04-30T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fruquintinib-capecitabine-combination-shows-promise-as-maintenance-therapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2025-04-30T04:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fruquintinib-capecitabine-combination-shows-promise-as-maintenance-therapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2025-04-30T04:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/low-lung-cancer-screening-rates-in-us-threaten-patient-outcomes-despite-proven-benefits 2025-04-30T02:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-lung-cancer-screening-rates-in-us-threaten-patient-outcomes-despite-proven-benefits 2025-04-30T02:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/cinclus-pharma-advances-linaprazan-glurate-toward-phase-iii-trials-for-acid-related-diseases 2025-04-30T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cinclus-pharma-advances-linaprazan-glurate-toward-phase-iii-trials-for-acid-related-diseases 2025-04-30T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-biopsy-approach-significantly-improves-survival-in-advanced-cancer-patients 2025-04-30T01:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-biopsy-approach-significantly-improves-survival-in-advanced-cancer-patients 2025-04-30T01:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/centivax-secures-45m-series-a-and-cepi-funding-to-advance-universal-influenza-vaccine-platform 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centivax-secures-45m-series-a-and-cepi-funding-to-advance-universal-influenza-vaccine-platform 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sparc-shares-drop-19-following-failed-psoriasis-drug-trial 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparc-shares-drop-19-following-failed-psoriasis-drug-trial 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-comprehensive-post-marketing-safety-comparison-reveals-differing-adverse-event-profiles-for-geographic-atrophy-treatments 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-comprehensive-post-marketing-safety-comparison-reveals-differing-adverse-event-profiles-for-geographic-atrophy-treatments 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-j-j-s-akeega-for-brca-positive-metastatic-prostate-cancer 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-j-j-s-akeega-for-brca-positive-metastatic-prostate-cancer 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-gene-therapy-gives-new-life-to-boy-with-death-sentence-immune-disease 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-gene-therapy-gives-new-life-to-boy-with-death-sentence-immune-disease 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/jeffs-brands-divests-u-s-e-commerce-assets-to-canadian-public-company-in-11-8-million-strategic-transaction 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeffs-brands-divests-u-s-e-commerce-assets-to-canadian-public-company-in-11-8-million-strategic-transaction 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3s-001-shows-breakthrough-efficacy-as-next-generation-kras-g12c-inhibitor-in-multiple-cancer-types 2025-04-29T23:57:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d3s-001-shows-breakthrough-efficacy-as-next-generation-kras-g12c-inhibitor-in-multiple-cancer-types 2025-04-29T23:57:26+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-challenges-fda-s-safety-claims-on-mifepristone-prompting-regulatory-scrutiny 2025-04-29T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-challenges-fda-s-safety-claims-on-mifepristone-prompting-regulatory-scrutiny 2025-04-29T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-to-showcase-new-data-on-liver-disease-treatments-at-easl-2025-congress 2025-04-29T22:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-to-showcase-new-data-on-liver-disease-treatments-at-easl-2025-congress 2025-04-29T22:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/proofpilot-and-digital-medicine-society-partner-to-develop-digital-tools-for-opioid-use-disorder-prevention 2025-04-29T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proofpilot-and-digital-medicine-society-partner-to-develop-digital-tools-for-opioid-use-disorder-prevention 2025-04-29T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/rafael-holdings-completes-25-million-rights-offering-to-fund-trappsol-cyclo-phase-3-trial-for-rare-disease 2025-04-29T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rafael-holdings-completes-25-million-rights-offering-to-fund-trappsol-cyclo-phase-3-trial-for-rare-disease 2025-04-29T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-icam-1-targeting-car-t-cell-therapy-shows-promise-in-advanced-thyroid-cancers 2025-04-29T19:37:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-icam-1-targeting-car-t-cell-therapy-shows-promise-in-advanced-thyroid-cancers 2025-04-29T19:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-exits-neuroscience-research-to-focus-on-core-therapeutic-areas 2025-04-29T19:37:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-exits-neuroscience-research-to-focus-on-core-therapeutic-areas 2025-04-29T19:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-seeks-eu-fast-track-status-for-lurbinectedin-tecentriq-combination-in-extensive-stage-sclc 2025-04-29T19:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmamar-seeks-eu-fast-track-status-for-lurbinectedin-tecentriq-combination-in-extensive-stage-sclc 2025-04-29T19:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/racial-and-ethnic-disparities-persist-in-pediatric-neuroblastoma-survival-despite-clinical-trial-access 2025-04-29T19:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racial-and-ethnic-disparities-persist-in-pediatric-neuroblastoma-survival-despite-clinical-trial-access 2025-04-29T19:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/central-florida-kidney-specialists-partners-with-clintrial-research-to-advance-nephrology-clinical-trials 2025-04-29T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/central-florida-kidney-specialists-partners-with-clintrial-research-to-advance-nephrology-clinical-trials 2025-04-29T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-fabhalta-poised-to-transform-treatment-landscape-for-multiple-complement-mediated-diseases 2025-04-29T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-fabhalta-poised-to-transform-treatment-landscape-for-multiple-complement-mediated-diseases 2025-04-29T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-discontinues-phase-3-trial-of-truqap-for-metastatic-prostate-cancer 2025-04-29T16:40:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-discontinues-phase-3-trial-of-truqap-for-metastatic-prostate-cancer 2025-04-29T16:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-medicine-joins-renovorx-s-phase-iii-pancreatic-cancer-trial-as-new-enrollment-site 2025-04-29T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-medicine-joins-renovorx-s-phase-iii-pancreatic-cancer-trial-as-new-enrollment-site 2025-04-29T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/forecast-2-world-first-trial-uses-tumor-organoids-to-personalize-bowel-cancer-treatment 2025-04-29T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forecast-2-world-first-trial-uses-tumor-organoids-to-personalize-bowel-cancer-treatment 2025-04-29T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/zyversa-s-ic-100-shows-promise-as-disease-modifying-treatment-for-parkinson-s-disease 2025-04-29T16:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyversa-s-ic-100-shows-promise-as-disease-modifying-treatment-for-parkinson-s-disease 2025-04-29T16:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-incyclix-bio-s-inx-315-for-ccne1-amplified-platinum-resistant-ovarian-cancer 2025-04-29T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-incyclix-bio-s-inx-315-for-ccne1-amplified-platinum-resistant-ovarian-cancer 2025-04-29T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-expands-into-aesthetics-with-strategic-investment-in-3d-printed-microneedle-technology 2025-04-29T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuity-biosciences-expands-into-aesthetics-with-strategic-investment-in-3d-printed-microneedle-technology 2025-04-29T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-advances-nv-387-as-potential-treatment-for-measles-amid-declining-vaccination-rates 2025-04-29T16:38:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-advances-nv-387-as-potential-treatment-for-measles-amid-declining-vaccination-rates 2025-04-29T16:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-s-pl9643-achieves-unprecedented-complete-symptom-resolution-in-dry-eye-disease-phase-3-trial 2025-04-29T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-s-pl9643-achieves-unprecedented-complete-symptom-resolution-in-dry-eye-disease-phase-3-trial 2025-04-29T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-diabetes-management-first-one-year-cgm-system-integrates-with-automated-insulin-delivery 2025-04-29T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-diabetes-management-first-one-year-cgm-system-integrates-with-automated-insulin-delivery 2025-04-29T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/morepen-laboratories-advances-development-of-resmetirom-for-nash-treatment 2025-04-29T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morepen-laboratories-advances-development-of-resmetirom-for-nash-treatment 2025-04-29T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-shorla-oncology-s-tepylute-100mg-first-ready-to-dilute-multi-dose-thiotepa-for-breast-and-ovarian-cancer 2025-04-29T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-shorla-oncology-s-tepylute-100mg-first-ready-to-dilute-multi-dose-thiotepa-for-breast-and-ovarian-cancer 2025-04-29T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-budget-cuts-linked-to-drug-approval-delays-as-small-biotech-faces-pdufa-postponement 2025-04-29T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-budget-cuts-linked-to-drug-approval-delays-as-small-biotech-faces-pdufa-postponement 2025-04-29T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/unravel-biosciences-advances-rvl-001-to-clinical-trials-for-rett-and-pitt-hopkins-syndromes-in-colombia 2025-04-29T16:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unravel-biosciences-advances-rvl-001-to-clinical-trials-for-rett-and-pitt-hopkins-syndromes-in-colombia 2025-04-29T16:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-enrolled-in-clinical-trial-evaluating-relizorb-for-pancreatitis-patients-with-epi 2025-04-29T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-enrolled-in-clinical-trial-evaluating-relizorb-for-pancreatitis-patients-with-epi 2025-04-29T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/acousia-therapeutics-reaches-50-enrollment-in-phase-2-trial-for-cisplatin-induced-hearing-loss-prevention 2025-04-29T16:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acousia-therapeutics-reaches-50-enrollment-in-phase-2-trial-for-cisplatin-induced-hearing-loss-prevention 2025-04-29T16:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/roosterbio-and-thermo-fisher-scientific-form-strategic-partnership-to-accelerate-cell-and-exosome-therapy-development 2025-04-29T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roosterbio-and-thermo-fisher-scientific-form-strategic-partnership-to-accelerate-cell-and-exosome-therapy-development 2025-04-29T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/tepylute-a-ready-to-dilute-formulation-of-thiotepa-now-available 2025-04-29T15:46:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tepylute-a-ready-to-dilute-formulation-of-thiotepa-now-available 2025-04-29T15:46:43+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-accelerates-23-billion-us-manufacturing-investment-as-ceo-warns-of-devastating-drug-pricing-controls 2025-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-accelerates-23-billion-us-manufacturing-investment-as-ceo-warns-of-devastating-drug-pricing-controls 2025-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-in-secondary-prevention-of-atrial-fibrillation 2025-04-29T14:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-promise-in-secondary-prevention-of-atrial-fibrillation 2025-04-29T14:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/atossa-therapeutics-unveils-smart-2-0-study-to-reduce-interval-breast-cancer-in-high-risk-women 2025-04-29T13:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atossa-therapeutics-unveils-smart-2-0-study-to-reduce-interval-breast-cancer-in-high-risk-women 2025-04-29T13:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-inhibitor-combination-shows-promise-in-primary-cns-lymphoma-trial 2025-04-29T13:35:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-inhibitor-combination-shows-promise-in-primary-cns-lymphoma-trial 2025-04-29T13:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy 2025-04-29T13:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy 2025-04-29T13:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/american-heart-association-awards-1m-to-study-glp-1-medications-impact-on-cardiovascular-risk 2025-04-29T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-heart-association-awards-1m-to-study-glp-1-medications-impact-on-cardiovascular-risk 2025-04-29T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-misses-deadline-for-stealth-biotherapeutics-rare-barth-syndrome-drug-elamipretide 2025-04-29T13:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-misses-deadline-for-stealth-biotherapeutics-rare-barth-syndrome-drug-elamipretide 2025-04-29T13:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/biomay-receives-fda-approval-for-cas9-nuclease-manufacturing-expanding-crispr-therapy-supply-chain 2025-04-29T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomay-receives-fda-approval-for-cas9-nuclease-manufacturing-expanding-crispr-therapy-supply-chain 2025-04-29T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-s-allonk-shows-promising-durability-in-b-cell-non-hodgkin-lymphoma-matching-car-t-efficacy 2025-04-29T13:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-s-allonk-shows-promising-durability-in-b-cell-non-hodgkin-lymphoma-matching-car-t-efficacy 2025-04-29T13:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/chla-pioneers-pig-heart-xenotransplantation-study-for-critically-ill-infants 2025-04-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chla-pioneers-pig-heart-xenotransplantation-study-for-critically-ill-infants 2025-04-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-commissioner-assures-drug-review-timelines-will-be-met-despite-mass-layoffs 2025-04-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-commissioner-assures-drug-review-timelines-will-be-met-despite-mass-layoffs 2025-04-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-and-sandoz-partner-on-ipilimumab-biosimilar-in-301-million-deal-to-expand-global-access 2025-04-29T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-and-sandoz-partner-on-ipilimumab-biosimilar-in-301-million-deal-to-expand-global-access 2025-04-29T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-therapeutics-to-showcase-breakthrough-prion-disease-treatment-at-asgct-annual-meeting 2025-04-29T10:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-therapeutics-to-showcase-breakthrough-prion-disease-treatment-at-asgct-annual-meeting 2025-04-29T10:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/shape-therapeutics-to-present-breakthrough-rna-editing-data-for-cns-therapies-at-asgct-annual-meeting 2025-04-29T10:34:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shape-therapeutics-to-present-breakthrough-rna-editing-data-for-cns-therapies-at-asgct-annual-meeting 2025-04-29T10:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-halts-phase-3-trial-of-capivasertib-for-metastatic-castration-resistant-prostate-cancer 2025-04-29T10:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-halts-phase-3-trial-of-capivasertib-for-metastatic-castration-resistant-prostate-cancer 2025-04-29T10:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/dyno-therapeutics-unveils-three-ai-designed-aav-capsids-for-enhanced-gene-therapy-delivery 2025-04-29T10:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyno-therapeutics-unveils-three-ai-designed-aav-capsids-for-enhanced-gene-therapy-delivery 2025-04-29T10:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/kytopen-forges-strategic-partnerships-to-revolutionize-cell-therapy-manufacturing-with-non-viral-engineering-platform 2025-04-29T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kytopen-forges-strategic-partnerships-to-revolutionize-cell-therapy-manufacturing-with-non-viral-engineering-platform 2025-04-29T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/therini-bio-s-thn391-shows-promise-in-phase-1a-trial-for-neurodegenerative-diseases 2025-04-29T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therini-bio-s-thn391-shows-promise-in-phase-1a-trial-for-neurodegenerative-diseases 2025-04-29T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fate-therapeutics-to-showcase-innovative-off-the-shelf-car-t-cell-platform-at-asgct-annual-meeting 2025-04-29T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fate-therapeutics-to-showcase-innovative-off-the-shelf-car-t-cell-platform-at-asgct-annual-meeting 2025-04-29T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-introduces-xm-liquid-biopsy-assay-to-monitor-immunotherapy-response-in-advanced-solid-tumors 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-introduces-xm-liquid-biopsy-assay-to-monitor-immunotherapy-response-in-advanced-solid-tumors 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncocyte-s-blood-based-transplant-rejection-assay-shows-long-term-clinical-validity-in-13-year-study 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncocyte-s-blood-based-transplant-rejection-assay-shows-long-term-clinical-validity-in-13-year-study 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/alxn1840-shows-promising-long-term-efficacy-and-safety-for-wilson-disease-at-easl-2025 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alxn1840-shows-promising-long-term-efficacy-and-safety-for-wilson-disease-at-easl-2025 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-unveils-groundbreaking-pre-therapy-test-for-ibd-biologic-response-prediction 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prometheus-laboratories-unveils-groundbreaking-pre-therapy-test-for-ibd-biologic-response-prediction 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bdr-pharmaceuticals-plans-100-million-u-s-expansion-to-boost-global-footprint 2025-04-29T07:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bdr-pharmaceuticals-plans-100-million-u-s-expansion-to-boost-global-footprint 2025-04-29T07:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/scaleready-awards-g-rex-grants-to-advance-novel-car-t-cell-therapy-manufacturing 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scaleready-awards-g-rex-grants-to-advance-novel-car-t-cell-therapy-manufacturing 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-with-psv359-in-perspective-therapeutics-phase-1-2a-trial-for-fap-a-positive-solid-tumors 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-with-psv359-in-perspective-therapeutics-phase-1-2a-trial-for-fap-a-positive-solid-tumors 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-to-showcase-ai-powered-real-world-oncology-data-research-at-ispor-2025 2025-04-29T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-to-showcase-ai-powered-real-world-oncology-data-research-at-ispor-2025 2025-04-29T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/community-engagement-emerges-as-critical-bridge-between-cancer-research-and-policy-development 2025-04-29T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-engagement-emerges-as-critical-bridge-between-cancer-research-and-policy-development 2025-04-29T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-shift-in-iga-nephropathy-treatment-novel-targeted-therapies-address-disease-mechanisms 2025-04-29T02:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-shift-in-iga-nephropathy-treatment-novel-targeted-therapies-address-disease-mechanisms 2025-04-29T02:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-approaches-for-relapsed-refractory-follicular-lymphoma-navigating-third-line-therapy-options 2025-04-29T02:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-treatment-approaches-for-relapsed-refractory-follicular-lymphoma-navigating-third-line-therapy-options 2025-04-29T02:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-gene-therapy-demonstrates-sustained-efficacy-in-knee-osteoarthritis-trial 2025-04-29T01:56:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-s-gene-therapy-demonstrates-sustained-efficacy-in-knee-osteoarthritis-trial 2025-04-29T01:56:45+00:00 hourly 0.9 https://trial.medpath.com/news/embark-trial-testosterone-levels-recover-in-most-men-after-prostate-cancer-treatment-suspension 2025-04-29T01:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embark-trial-testosterone-levels-recover-in-most-men-after-prostate-cancer-treatment-suspension 2025-04-29T01:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/stablepharma-begins-phase-1-trial-of-world-s-first-fridge-free-tetanus-diphtheria-vaccine 2025-04-29T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stablepharma-begins-phase-1-trial-of-world-s-first-fridge-free-tetanus-diphtheria-vaccine 2025-04-29T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/deepull-raises-eur50-million-in-series-c-to-advance-rapid-sepsis-diagnostic-technology 2025-04-29T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepull-raises-eur50-million-in-series-c-to-advance-rapid-sepsis-diagnostic-technology 2025-04-29T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/capsida-biotherapeutics-advances-novel-gene-therapies-for-cns-disorders-ahead-of-asgct-2025 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsida-biotherapeutics-advances-novel-gene-therapies-for-cns-disorders-ahead-of-asgct-2025 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-expands-can10-development-to-target-treatment-resistant-atopic-dermatitis 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-expands-can10-development-to-target-treatment-resistant-atopic-dermatitis 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fyr-partners-with-mayo-clinic-to-develop-blood-based-biomarkers-for-parkinson-s-disease-using-ai-enabled-platform 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fyr-partners-with-mayo-clinic-to-develop-blood-based-biomarkers-for-parkinson-s-disease-using-ai-enabled-platform 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acc-recommends-first-line-obesity-medications-as-prescribing-disparities-persist-for-semaglutide-and-tirzepatide 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acc-recommends-first-line-obesity-medications-as-prescribing-disparities-persist-for-semaglutide-and-tirzepatide 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-bioinvent-s-bi-1808-for-cutaneous-t-cell-lymphoma 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-bioinvent-s-bi-1808-for-cutaneous-t-cell-lymphoma 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/invikafusp-alfa-demonstrates-promising-activity-in-immune-checkpoint-inhibitor-resistant-solid-tumors 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invikafusp-alfa-demonstrates-promising-activity-in-immune-checkpoint-inhibitor-resistant-solid-tumors 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transverse-medical-secures-over-10m-in-series-b2-funding-to-advance-stroke-prevention-technology 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transverse-medical-secures-over-10m-in-series-b2-funding-to-advance-stroke-prevention-technology 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapy-shows-100-response-rate-in-refractory-cd30-lymphoma-patients 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-shows-100-response-rate-in-refractory-cd30-lymphoma-patients 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/frontier-medicines-presents-breakthrough-data-on-fmc-220-first-in-class-p53-y220c-activator-for-cancer-treatment 2025-04-28T22:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontier-medicines-presents-breakthrough-data-on-fmc-220-first-in-class-p53-y220c-activator-for-cancer-treatment 2025-04-28T22:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/oramed-pharmaceuticals-invests-36-9-million-in-alpha-tau-medical-to-advance-cancer-radiation-therapy 2025-04-28T22:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oramed-pharmaceuticals-invests-36-9-million-in-alpha-tau-medical-to-advance-cancer-radiation-therapy 2025-04-28T22:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-immunotherapy-trial-aims-to-reprogram-immune-system-in-type-1-diabetes 2025-04-28T22:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-immunotherapy-trial-aims-to-reprogram-immune-system-in-type-1-diabetes 2025-04-28T22:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-tar-200-shows-promising-results-in-bcg-unresponsive-bladder-cancer-trial 2025-04-28T22:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-tar-200-shows-promising-results-in-bcg-unresponsive-bladder-cancer-trial 2025-04-28T22:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-senate-approves-prescription-drug-affordability-board-to-combat-rising-medication-costs 2025-04-28T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-senate-approves-prescription-drug-affordability-board-to-combat-rising-medication-costs 2025-04-28T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-appoints-david-l-hallal-as-ceo-strengthens-leadership-team-ahead-of-apitegromab-launch-for-sma 2025-04-28T20:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-appoints-david-l-hallal-as-ceo-strengthens-leadership-team-ahead-of-apitegromab-launch-for-sma 2025-04-28T20:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/histosonics-histotripsy-system-achieves-90-local-tumor-control-at-12-months-in-liver-cancer-trials 2025-04-28T20:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histosonics-histotripsy-system-achieves-90-local-tumor-control-at-12-months-in-liver-cancer-trials 2025-04-28T20:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-breakthrough-could-replace-traditional-cancer-treatments-in-select-patients 2025-04-28T20:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-breakthrough-could-replace-traditional-cancer-treatments-in-select-patients 2025-04-28T20:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-secures-key-chinese-patent-for-covid-19-treatment-rhb-107 2025-04-28T19:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-secures-key-chinese-patent-for-covid-19-treatment-rhb-107 2025-04-28T19:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmasyntez-to-launch-three-innovative-drugs-with-blockbuster-potential-in-2025-2026 2025-04-28T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmasyntez-to-launch-three-innovative-drugs-with-blockbuster-potential-in-2025-2026 2025-04-28T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-to-launch-sanofi-s-beyfortus-in-india-for-rsv-prevention-in-infants 2025-04-28T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-to-launch-sanofi-s-beyfortus-in-india-for-rsv-prevention-in-infants 2025-04-28T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/cg-oncology-s-bladder-cancer-drug-shows-promising-durability-in-phase-3-trial 2025-04-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cg-oncology-s-bladder-cancer-drug-shows-promising-durability-in-phase-3-trial 2025-04-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/yale-s-experimental-cancer-vaccine-shows-remarkable-success-in-canine-clinical-trials 2025-04-28T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-s-experimental-cancer-vaccine-shows-remarkable-success-in-canine-clinical-trials 2025-04-28T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-reports-promising-phase-1-data-for-anchored-il-12-drug-conjugate-in-solid-tumors 2025-04-28T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ankyra-therapeutics-reports-promising-phase-1-data-for-anchored-il-12-drug-conjugate-in-solid-tumors 2025-04-28T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/g8-frailty-assessment-tool-predicts-docetaxel-tolerability-in-metastatic-prostate-cancer 2025-04-28T19:00:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/g8-frailty-assessment-tool-predicts-docetaxel-tolerability-in-metastatic-prostate-cancer 2025-04-28T19:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ai-model-progrxn-bca-significantly-improves-nmibc-progression-risk-prediction 2025-04-28T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ai-model-progrxn-bca-significantly-improves-nmibc-progression-risk-prediction 2025-04-28T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-986365-shows-promise-in-phase-3-trial-for-advanced-prostate-cancer-resistant-to-standard-therapies 2025-04-28T16:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-986365-shows-promise-in-phase-3-trial-for-advanced-prostate-cancer-resistant-to-standard-therapies 2025-04-28T16:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-s-ruvidar-shows-promise-as-dub-inhibitor-in-cancer-treatment-breakthrough 2025-04-28T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-s-ruvidar-shows-promise-as-dub-inhibitor-in-cancer-treatment-breakthrough 2025-04-28T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-immunochemotherapy-shows-promising-results-in-locally-advanced-oral-squamous-cell-carcinoma 2025-04-28T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-immunochemotherapy-shows-promising-results-in-locally-advanced-oral-squamous-cell-carcinoma 2025-04-28T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-unveils-loop-ai-powered-platform-revolutionizes-oncology-target-discovery 2025-04-28T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-unveils-loop-ai-powered-platform-revolutionizes-oncology-target-discovery 2025-04-28T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-delcath-s-hepzato-for-phase-2-trial-in-liver-dominant-metastatic-breast-cancer 2025-04-28T16:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-delcath-s-hepzato-for-phase-2-trial-in-liver-dominant-metastatic-breast-cancer 2025-04-28T16:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/be-biopharma-to-present-promising-nonclinical-data-for-novel-b-cell-therapy-in-hypophosphatasia-treatment 2025-04-28T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/be-biopharma-to-present-promising-nonclinical-data-for-novel-b-cell-therapy-in-hypophosphatasia-treatment 2025-04-28T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/metrion-biosciences-unveils-breakthrough-nav1-9-screening-assay-to-accelerate-non-opioid-pain-therapeutics-development 2025-04-28T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metrion-biosciences-unveils-breakthrough-nav1-9-screening-assay-to-accelerate-non-opioid-pain-therapeutics-development 2025-04-28T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-to-present-new-zymfentra-r-data-for-ibd-management-at-2025-digestive-disease-week 2025-04-28T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-to-present-new-zymfentra-r-data-for-ibd-management-at-2025-digestive-disease-week 2025-04-28T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-initiates-phase-1-trial-combining-ziftomenib-with-imatinib-for-advanced-gist-treatment 2025-04-28T16:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-initiates-phase-1-trial-combining-ziftomenib-with-imatinib-for-advanced-gist-treatment 2025-04-28T16:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/cellectis-advances-gene-editing-with-non-viral-talen-technology-and-tale-base-editors-at-asgct-2025 2025-04-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectis-advances-gene-editing-with-non-viral-talen-technology-and-tale-base-editors-at-asgct-2025 2025-04-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/spero-therapeutics-appoints-esther-rajavelu-as-president-and-chief-executive-officer 2025-04-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spero-therapeutics-appoints-esther-rajavelu-as-president-and-chief-executive-officer 2025-04-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-blue-cross-and-blue-shield-approves-coverage-for-reactiv8-neurostimulation-therapy-for-chronic-low-back-pain 2025-04-28T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthem-blue-cross-and-blue-shield-approves-coverage-for-reactiv8-neurostimulation-therapy-for-chronic-low-back-pain 2025-04-28T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/tg-c-shows-promise-as-first-disease-modifying-therapy-for-knee-osteoarthritis-with-15-year-safety-data 2025-04-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-c-shows-promise-as-first-disease-modifying-therapy-for-knee-osteoarthritis-with-15-year-safety-data 2025-04-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-surpasses-2-2-billion-in-2025-contract-orders-expands-global-biomanufacturing-capacity 2025-04-28T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-surpasses-2-2-billion-in-2025-contract-orders-expands-global-biomanufacturing-capacity 2025-04-28T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-to-acquire-springworks-therapeutics-in-3-9-billion-deal-for-rare-disease-portfolio 2025-04-28T14:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-to-acquire-springworks-therapeutics-in-3-9-billion-deal-for-rare-disease-portfolio 2025-04-28T14:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-to-acquire-antev-for-75-million-gaining-novel-gnrh-antagonist-for-prostate-conditions 2025-04-28T14:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-to-acquire-antev-for-75-million-gaining-novel-gnrh-antagonist-for-prostate-conditions 2025-04-28T14:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-lenire-device-shows-91-5-success-rate-in-real-world-tinnitus-treatment-study 2025-04-28T14:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-lenire-device-shows-91-5-success-rate-in-real-world-tinnitus-treatment-study 2025-04-28T14:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-secures-600-million-non-dilutive-funding-from-oberland-capital-for-rare-disease-drug-development 2025-04-28T14:36:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-secures-600-million-non-dilutive-funding-from-oberland-capital-for-rare-disease-drug-development 2025-04-28T14:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/talus-bio-unveils-promising-preclinical-data-on-novel-transcription-factor-inhibitors-at-aacr-2025 2025-04-28T13:44:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talus-bio-unveils-promising-preclinical-data-on-novel-transcription-factor-inhibitors-at-aacr-2025 2025-04-28T13:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/new-biomarker-for-early-parkinson-s-detection-shows-over-90-accuracy-in-clinical-trials 2025-04-28T13:42:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-biomarker-for-early-parkinson-s-detection-shows-over-90-accuracy-in-clinical-trials 2025-04-28T13:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/purespring-s-ps-002-receives-ema-orphan-drug-designation-for-iga-nephropathy-treatment 2025-04-28T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purespring-s-ps-002-receives-ema-orphan-drug-designation-for-iga-nephropathy-treatment 2025-04-28T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/news/immvira-reports-favorable-safety-profile-for-oncolytic-virus-mvr-c5252-in-phase-i-glioma-trial 2025-04-28T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immvira-reports-favorable-safety-profile-for-oncolytic-virus-mvr-c5252-in-phase-i-glioma-trial 2025-04-28T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-pharmaceuticals-advances-novel-sublingual-semaglutide-formulation-to-challenge-injectable-glp-1-market 2025-04-28T13:40:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-pharmaceuticals-advances-novel-sublingual-semaglutide-formulation-to-challenge-injectable-glp-1-market 2025-04-28T13:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/pretomanid-price-drops-25-boosting-access-to-life-saving-tb-treatment-across-africa 2025-04-28T13:40:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pretomanid-price-drops-25-boosting-access-to-life-saving-tb-treatment-across-africa 2025-04-28T13:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-commits-2-billion-to-expand-us-manufacturing-and-r-d-capabilities 2025-04-28T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-commits-2-billion-to-expand-us-manufacturing-and-r-d-capabilities 2025-04-28T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-adma-biologics-innovative-yield-enhancement-process-for-immune-globulin-production 2025-04-28T13:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-adma-biologics-innovative-yield-enhancement-process-for-immune-globulin-production 2025-04-28T13:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-to-acquire-ajinomoto-althea-expanding-us-fill-finish-capabilities 2025-04-28T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pci-pharma-services-to-acquire-ajinomoto-althea-expanding-us-fill-finish-capabilities 2025-04-28T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-unveils-promising-preclinical-data-for-stx-003-mrna-therapy-targeting-solid-tumors 2025-04-28T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-unveils-promising-preclinical-data-for-stx-003-mrna-therapy-targeting-solid-tumors 2025-04-28T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-launches-first-tissue-test-with-comprehensive-multiomic-analysis-for-cancer-profiling 2025-04-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-launches-first-tissue-test-with-comprehensive-multiomic-analysis-for-cancer-profiling 2025-04-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-reports-promising-results-for-zoldonrasib-in-kras-g12d-mutant-lung-cancer 2025-04-28T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-reports-promising-results-for-zoldonrasib-in-kras-g12d-mutant-lung-cancer 2025-04-28T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-navi-partners-with-first-securities-for-ipo-aims-to-accelerate-global-medtech-expansion 2025-04-28T10:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-navi-partners-with-first-securities-for-ipo-aims-to-accelerate-global-medtech-expansion 2025-04-28T10:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-blackfinbio-s-novel-gene-therapy-trial-for-rare-childhood-neurological-disease-spg47 2025-04-28T10:34:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-blackfinbio-s-novel-gene-therapy-trial-for-rare-childhood-neurological-disease-spg47 2025-04-28T10:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/radspherin-r-shows-promising-18-month-results-in-ovarian-cancer-trial-with-90-recurrence-free-rate 2025-04-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radspherin-r-shows-promising-18-month-results-in-ovarian-cancer-trial-with-90-recurrence-free-rate 2025-04-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-and-ferrer-form-eur500-million-partnership-to-commercialize-pridopidine-for-huntington-s-disease-in-europe 2025-04-28T08:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prilenia-and-ferrer-form-eur500-million-partnership-to-commercialize-pridopidine-for-huntington-s-disease-in-europe 2025-04-28T08:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-faces-fda-setback-for-brain-cancer-imaging-agent 2025-04-28T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-pharmaceuticals-faces-fda-setback-for-brain-cancer-imaging-agent 2025-04-28T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-s-logic-gated-car-nk-cell-therapy-shows-promising-results-in-aml-clinical-trial 2025-04-28T07:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-s-logic-gated-car-nk-cell-therapy-shows-promising-results-in-aml-clinical-trial 2025-04-28T07:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-presents-promising-preclinical-data-for-cdk2-molecular-glue-degrader-in-hr-positive-breast-cancer-at-aacr-2025 2025-04-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-presents-promising-preclinical-data-for-cdk2-molecular-glue-degrader-in-hr-positive-breast-cancer-at-aacr-2025 2025-04-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/total-telcom-subsidiary-secures-100000-plus-royalties-in-strategic-licensing-deal-for-heater-controllers 2025-04-28T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/total-telcom-subsidiary-secures-100000-plus-royalties-in-strategic-licensing-deal-for-heater-controllers 2025-04-28T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/elpis-biopharmaceuticals-advances-multi-mechanism-armored-car-t-platform-for-solid-tumors 2025-04-28T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elpis-biopharmaceuticals-advances-multi-mechanism-armored-car-t-platform-for-solid-tumors 2025-04-28T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-presents-preclinical-pharmacokinetics-data-for-cd38-sada-pretargeted-radioimmunotherapy-at-aacr-2025 2025-04-28T04:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-mabs-presents-preclinical-pharmacokinetics-data-for-cd38-sada-pretargeted-radioimmunotherapy-at-aacr-2025 2025-04-28T04:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-presents-promising-preclinical-data-on-novel-mesothelin-targeting-adc-at-aacr-2025 2025-04-28T04:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-presents-promising-preclinical-data-on-novel-mesothelin-targeting-adc-at-aacr-2025 2025-04-28T04:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-biological-aging-linked-to-30-higher-dementia-risk-new-study-finds 2025-04-28T03:44:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-biological-aging-linked-to-30-higher-dementia-risk-new-study-finds 2025-04-28T03:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/depression-rates-surge-60-over-past-decade-new-nchs-data-reveals 2025-04-28T03:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/depression-rates-surge-60-over-past-decade-new-nchs-data-reveals 2025-04-28T03:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-comprehensive-ban-on-petroleum-based-food-dyes-by-2026 2025-04-28T03:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-announces-comprehensive-ban-on-petroleum-based-food-dyes-by-2026 2025-04-28T03:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-confirms-proteinuria-as-primary-endpoint-for-dimerix-s-dmx-200-phase-3-fsgs-trial 2025-04-28T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-confirms-proteinuria-as-primary-endpoint-for-dimerix-s-dmx-200-phase-3-fsgs-trial 2025-04-28T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/fakeeh-care-inks-mou-with-fosun-pharma-to-develop-cell-gene-therapies 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fakeeh-care-inks-mou-with-fosun-pharma-to-develop-cell-gene-therapies 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-performs-first-easee-brain-implant-surgery-for-drug-resistant-epilepsy-at-newcastle-hospitals 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-performs-first-easee-brain-implant-surgery-for-drug-resistant-epilepsy-at-newcastle-hospitals 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-lipid-association-advocates-for-universal-lipoprotein-a-testing-to-enhance-cardiovascular-risk-assessment 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-lipid-association-advocates-for-universal-lipoprotein-a-testing-to-enhance-cardiovascular-risk-assessment 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-targeting-cav-1-protein-shows-promise-in-preserving-memory-function-in-alzheimer-s-disease 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-therapy-targeting-cav-1-protein-shows-promise-in-preserving-memory-function-in-alzheimer-s-disease 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-coverage-of-glp-1-obesity-drugs-could-add-47-7-billion-to-federal-spending-over-10-years 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-coverage-of-glp-1-obesity-drugs-could-add-47-7-billion-to-federal-spending-over-10-years 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liberty-gold-ceo-cal-everett-retires-after-eight-years-dr-jon-gilligan-named-new-president-and-ceo 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liberty-gold-ceo-cal-everett-retires-after-eight-years-dr-jon-gilligan-named-new-president-and-ceo 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-initiates-phase-1-trial-of-cd38-sada-radioimmunotherapy-for-relapsed-non-hodgkin-lymphoma 2025-04-27T22:37:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-mabs-initiates-phase-1-trial-of-cd38-sada-radioimmunotherapy-for-relapsed-non-hodgkin-lymphoma 2025-04-27T22:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/precede-biosciences-unveils-breakthrough-liquid-biopsy-platform-for-tumor-gene-expression-at-aacr-2025 2025-04-27T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precede-biosciences-unveils-breakthrough-liquid-biopsy-platform-for-tumor-gene-expression-at-aacr-2025 2025-04-27T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-considers-accelerating-obesity-drug-launch-following-landmark-roche-partnership 2025-04-27T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-considers-accelerating-obesity-drug-launch-following-landmark-roche-partnership 2025-04-27T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-off-the-shelf-car-nk-cell-therapy-shows-complete-remission-in-relapsed-aml-patients 2025-04-27T22:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-off-the-shelf-car-nk-cell-therapy-shows-complete-remission-in-relapsed-aml-patients 2025-04-27T22:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/novel-topical-gel-successfully-treats-painful-skin-rash-from-colorectal-cancer-therapy 2025-04-27T22:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-topical-gel-successfully-treats-painful-skin-rash-from-colorectal-cancer-therapy 2025-04-27T22:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/abpro-and-celltrion-s-abp-102-ct-p72-shows-promise-as-best-in-class-her2-t-cell-engager 2025-04-27T19:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abpro-and-celltrion-s-abp-102-ct-p72-shows-promise-as-best-in-class-her2-t-cell-engager 2025-04-27T19:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-groundbreaking-aveir-leadless-pacemaker-shows-promise-in-first-in-human-conduction-system-pacing-study 2025-04-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-groundbreaking-aveir-leadless-pacemaker-shows-promise-in-first-in-human-conduction-system-pacing-study 2025-04-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-alone-successfully-treats-multiple-cancer-types-with-mmrd-mutation-eliminating-need-for-surgery 2025-04-27T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-alone-successfully-treats-multiple-cancer-types-with-mmrd-mutation-eliminating-need-for-surgery 2025-04-27T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/dostarlimab-shows-promise-in-eliminating-need-for-surgery-across-multiple-dmmr-cancer-types 2025-04-27T19:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dostarlimab-shows-promise-in-eliminating-need-for-surgery-across-multiple-dmmr-cancer-types 2025-04-27T19:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-breakthrough-pembrolizumab-doubles-disease-free-survival-in-locally-advanced-head-and-neck-cancer 2025-04-27T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-breakthrough-pembrolizumab-doubles-disease-free-survival-in-locally-advanced-head-and-neck-cancer 2025-04-27T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-anticipates-chmp-opinion-on-nirogacestat-for-desmoid-tumors-in-q2-2025 2025-04-27T16:34:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springworks-anticipates-chmp-opinion-on-nirogacestat-for-desmoid-tumors-in-q2-2025 2025-04-27T16:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/uniphar-launches-10th-cell-and-gene-therapy-project-expanding-global-access-to-advanced-treatments 2025-04-27T13:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniphar-launches-10th-cell-and-gene-therapy-project-expanding-global-access-to-advanced-treatments 2025-04-27T13:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/zenflow-s-spring-system-shows-durable-three-year-benefits-for-bph-patients-in-landmark-study 2025-04-27T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenflow-s-spring-system-shows-durable-three-year-benefits-for-bph-patients-in-landmark-study 2025-04-27T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-volt-pfa-system-shows-impressive-12-month-results-for-atrial-fibrillation-treatment 2025-04-27T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-volt-pfa-system-shows-impressive-12-month-results-for-atrial-fibrillation-treatment 2025-04-27T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-shows-improved-survival-in-newly-diagnosed-glioblastoma-patients-with-high-immune-infiltration 2025-04-27T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-shows-improved-survival-in-newly-diagnosed-glioblastoma-patients-with-high-immune-infiltration 2025-04-27T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-gras-status-to-bestzyme-s-melliatm-brazzein-advancing-zero-calorie-sweetener-market 2025-04-27T04:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-gras-status-to-bestzyme-s-melliatm-brazzein-advancing-zero-calorie-sweetener-market 2025-04-27T04:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-afferatm-pfa-technologies-show-promising-results-for-atrial-fibrillation-treatment 2025-04-27T02:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-afferatm-pfa-technologies-show-promising-results-for-atrial-fibrillation-treatment 2025-04-27T02:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/lee-health-heart-institute-reaches-100-patient-milestone-in-global-leapps-stroke-prevention-trial 2025-04-27T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lee-health-heart-institute-reaches-100-patient-milestone-in-global-leapps-stroke-prevention-trial 2025-04-27T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/structured-linezolid-dose-reduction-shows-promise-in-drug-resistant-tb-treatment 2025-04-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structured-linezolid-dose-reduction-shows-promise-in-drug-resistant-tb-treatment 2025-04-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-indigenous-hpv-test-kits-for-cervical-cancer-screening 2025-04-26T22:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-first-indigenous-hpv-test-kits-for-cervical-cancer-screening 2025-04-26T22:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/lifitegrast-shows-long-term-safety-and-efficacy-for-dry-eye-disease-in-7-year-analysis 2025-04-26T22:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifitegrast-shows-long-term-safety-and-efficacy-for-dry-eye-disease-in-7-year-analysis 2025-04-26T22:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-trofinetide-as-first-ever-treatment-for-rett-syndrome-opening-new-era-for-rare-genetic-disorder 2025-04-26T22:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-trofinetide-as-first-ever-treatment-for-rett-syndrome-opening-new-era-for-rare-genetic-disorder 2025-04-26T22:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-tepezza-for-thyroid-eye-disease-first-targeted-treatment-in-eu 2025-04-26T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-of-tepezza-for-thyroid-eye-disease-first-targeted-treatment-in-eu 2025-04-26T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-hugo-robotic-surgery-system-meets-primary-endpoints-in-landmark-urologic-trial 2025-04-26T19:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-hugo-robotic-surgery-system-meets-primary-endpoints-in-landmark-urologic-trial 2025-04-26T19:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/spyglass-pharma-s-iol-mounted-drug-delivery-platform-shows-promising-18-month-results-for-glaucoma-patients 2025-04-26T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyglass-pharma-s-iol-mounted-drug-delivery-platform-shows-promising-18-month-results-for-glaucoma-patients 2025-04-26T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-receives-positive-chmp-opinions-for-denosumab-biosimilars-in-europe 2025-04-26T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-receives-positive-chmp-opinions-for-denosumab-biosimilars-in-europe 2025-04-26T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-secures-2-35-million-in-public-offering-to-advance-cancer-immunotherapy-trials 2025-04-26T08:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-secures-2-35-million-in-public-offering-to-advance-cancer-immunotherapy-trials 2025-04-26T08:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-to-present-groundbreaking-cancer-research-at-aacr-annual-meeting-2025 2025-04-26T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-to-present-groundbreaking-cancer-research-at-aacr-annual-meeting-2025 2025-04-26T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/keymed-biosciences-advances-novel-cdh17-targeted-adc-for-gastrointestinal-cancers-with-ind-approval-in-china 2025-04-26T04:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keymed-biosciences-advances-novel-cdh17-targeted-adc-for-gastrointestinal-cancers-with-ind-approval-in-china 2025-04-26T04:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-updates-guidelines-to-recommend-dpyd-testing-before-fluoropyrimidine-chemotherapy 2025-04-26T03:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-updates-guidelines-to-recommend-dpyd-testing-before-fluoropyrimidine-chemotherapy 2025-04-26T03:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-age-specific-disease-burdens-in-pediatric-and-adolescent-atopic-dermatitis-patients 2025-04-26T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-age-specific-disease-burdens-in-pediatric-and-adolescent-atopic-dermatitis-patients 2025-04-26T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-ink-launches-triallens-ai-powered-analytics-dashboard-transforms-clinical-trial-data-management 2025-04-26T02:33:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-ink-launches-triallens-ai-powered-analytics-dashboard-transforms-clinical-trial-data-management 2025-04-26T02:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-withdraws-eu-application-for-troriluzole-in-spinocerebellar-ataxia-rbc-remains-optimistic 2025-04-26T02:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-withdraws-eu-application-for-troriluzole-in-spinocerebellar-ataxia-rbc-remains-optimistic 2025-04-26T02:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-omniasecure-world-s-smallest-defibrillation-lead-for-cardiac-patients 2025-04-26T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-omniasecure-world-s-smallest-defibrillation-lead-for-cardiac-patients 2025-04-26T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-reports-promising-3-month-data-for-omnypulse-platform-in-atrial-fibrillation-treatment 2025-04-26T01:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-reports-promising-3-month-data-for-omnypulse-platform-in-atrial-fibrillation-treatment 2025-04-26T01:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/proposed-25-pharmaceutical-tariffs-could-increase-us-drug-costs-by-51-billion-annually 2025-04-25T23:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proposed-25-pharmaceutical-tariffs-could-increase-us-drug-costs-by-51-billion-annually 2025-04-25T23:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-additional-trial-for-novavax-covid-19-vaccine-before-full-approval 2025-04-25T22:40:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requests-additional-trial-for-novavax-covid-19-vaccine-before-full-approval 2025-04-25T22:40:26+00:00 hourly 0.9 https://trial.medpath.com/news/veracyte-expands-decipher-prostate-test-to-metastatic-cancer-patients-offering-new-treatment-guidance-tool 2025-04-25T22:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veracyte-expands-decipher-prostate-test-to-metastatic-cancer-patients-offering-new-treatment-guidance-tool 2025-04-25T22:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-precise-mrd-test-shows-promise-for-personalized-treatment-in-renal-cell-carcinoma 2025-04-25T22:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-precise-mrd-test-shows-promise-for-personalized-treatment-in-renal-cell-carcinoma 2025-04-25T22:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-researchers-present-breakthrough-cancer-therapies-at-aacr-2025 2025-04-25T22:38:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-researchers-present-breakthrough-cancer-therapies-at-aacr-2025 2025-04-25T22:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/aacr-annual-meeting-2025-to-bridge-gap-between-cancer-science-and-clinical-practice 2025-04-25T22:37:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aacr-annual-meeting-2025-to-bridge-gap-between-cancer-science-and-clinical-practice 2025-04-25T22:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-to-showcase-advanced-liquid-biopsy-innovations-at-aacr-2025 2025-04-25T20:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/billiontoone-to-showcase-advanced-liquid-biopsy-innovations-at-aacr-2025 2025-04-25T20:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/uk-court-of-appeal-grants-astrazeneca-interim-injunction-against-glenmark-s-generic-dapagliflozin 2025-04-25T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-court-of-appeal-grants-astrazeneca-interim-injunction-against-glenmark-s-generic-dapagliflozin 2025-04-25T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-initiates-first-in-human-trial-of-ndi-219216-for-msi-h-tumors-resistant-to-standard-therapies 2025-04-25T19:37:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimbus-therapeutics-initiates-first-in-human-trial-of-ndi-219216-for-msi-h-tumors-resistant-to-standard-therapies 2025-04-25T19:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-fl-501-shows-promise-in-reversing-cancer-cachexia-in-preclinical-studies 2025-04-25T19:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-fl-501-shows-promise-in-reversing-cancer-cachexia-in-preclinical-studies 2025-04-25T19:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-announces-900-million-manufacturing-expansion-in-ohio-creating-350-new-jobs 2025-04-25T19:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-announces-900-million-manufacturing-expansion-in-ohio-creating-350-new-jobs 2025-04-25T19:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-secures-fda-approval-for-novel-cancer-drug-while-partner-summit-therapeutics-faces-sharp-stock-decline 2025-04-25T19:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-secures-fda-approval-for-novel-cancer-drug-while-partner-summit-therapeutics-faces-sharp-stock-decline 2025-04-25T19:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-researchers-present-breakthrough-cancer-studies-at-aacr-2025-annual-meeting 2025-04-25T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-researchers-present-breakthrough-cancer-studies-at-aacr-2025-annual-meeting 2025-04-25T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/smart-drug-delivery-systems-market-poised-for-17-growth-as-chronic-disease-management-evolves 2025-04-25T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-drug-delivery-systems-market-poised-for-17-growth-as-chronic-disease-management-evolves 2025-04-25T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-withdraws-eu-application-for-spinocerebellar-ataxia-drug-dazluma 2025-04-25T19:36:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-withdraws-eu-application-for-spinocerebellar-ataxia-drug-dazluma 2025-04-25T19:36:04+00:00 hourly 0.9 https://trial.medpath.com/news/emercell-receives-ema-approval-to-study-allogeneic-nk-cell-therapy-for-diffuse-large-b-cell-lymphoma 2025-04-25T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emercell-receives-ema-approval-to-study-allogeneic-nk-cell-therapy-for-diffuse-large-b-cell-lymphoma 2025-04-25T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-role-in-regulatory-reliance-for-post-approval-changes 2025-04-25T19:35:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-role-in-regulatory-reliance-for-post-approval-changes 2025-04-25T19:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/uk-court-of-appeal-grants-astrazeneca-injunction-against-glenmark-s-diabetes-generic 2025-04-25T19:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-court-of-appeal-grants-astrazeneca-injunction-against-glenmark-s-diabetes-generic 2025-04-25T19:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/suven-pharmaceuticals-and-cohance-lifesciences-merger-approved-creating-1-billion-cdmo-powerhouse 2025-04-25T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suven-pharmaceuticals-and-cohance-lifesciences-merger-approved-creating-1-billion-cdmo-powerhouse 2025-04-25T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/olema-s-kat6-inhibitor-op-3136-shows-promising-anti-tumor-activity-across-multiple-cancer-types 2025-04-25T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olema-s-kat6-inhibitor-op-3136-shows-promising-anti-tumor-activity-across-multiple-cancer-types 2025-04-25T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/pneumonia-antibiotic-piperacillin-shows-promise-as-targeted-lyme-disease-treatment-at-100-fold-lower-doses 2025-04-25T18:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pneumonia-antibiotic-piperacillin-shows-promise-as-targeted-lyme-disease-treatment-at-100-fold-lower-doses 2025-04-25T18:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-limited-sets-new-benchmark-with-india-s-largest-diabetes-real-world-evidence-study 2025-04-25T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-limited-sets-new-benchmark-with-india-s-largest-diabetes-real-world-evidence-study 2025-04-25T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-s-cd47-inhibitor-combination-with-keytruda-fails-in-dual-phase-ii-trials 2025-04-25T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-s-cd47-inhibitor-combination-with-keytruda-fails-in-dual-phase-ii-trials 2025-04-25T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-s-visugromab-shows-promise-in-enhancing-antibody-drug-conjugate-efficacy-by-blocking-gdf-15 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalym-s-visugromab-shows-promise-in-enhancing-antibody-drug-conjugate-efficacy-by-blocking-gdf-15 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdr-life-s-novel-t-cell-engagers-show-superior-potency-against-solid-tumors-in-preclinical-studies 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdr-life-s-novel-t-cell-engagers-show-superior-potency-against-solid-tumors-in-preclinical-studies 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vivavision-s-vvn461-shows-promising-results-in-phase-2-trial-for-non-infectious-anterior-uveitis 2025-04-25T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivavision-s-vvn461-shows-promising-results-in-phase-2-trial-for-non-infectious-anterior-uveitis 2025-04-25T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-approval-of-oczyesa-for-acromegaly-treatment-in-the-eu 2025-04-25T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-recommends-approval-of-oczyesa-for-acromegaly-treatment-in-the-eu 2025-04-25T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-sephience-receives-positive-chmp-opinion-for-phenylketonuria-treatment-across-all-age-groups 2025-04-25T16:35:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-sephience-receives-positive-chmp-opinion-for-phenylketonuria-treatment-across-all-age-groups 2025-04-25T16:35:57+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trial-launches-to-test-sipavibart-as-potential-long-covid-treatment 2025-04-25T16:35:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trial-launches-to-test-sipavibart-as-potential-long-covid-treatment 2025-04-25T16:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-restructures-abandons-autoimmune-program-to-focus-on-cancer-cell-therapies 2025-04-25T16:35:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-restructures-abandons-autoimmune-program-to-focus-on-cancer-cell-therapies 2025-04-25T16:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/evorpacept-keytruda-combination-fails-to-meet-primary-endpoints-in-head-and-neck-cancer-trials 2025-04-25T16:35:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evorpacept-keytruda-combination-fails-to-meet-primary-endpoints-in-head-and-neck-cancer-trials 2025-04-25T16:35:39+00:00 hourly 0.9 https://trial.medpath.com/news/queen-elizabeth-hospital-leads-uk-recruitment-in-global-astrazeneca-heart-failure-trial 2025-04-25T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/queen-elizabeth-hospital-leads-uk-recruitment-in-global-astrazeneca-heart-failure-trial 2025-04-25T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/clearb-therapeutics-to-present-promising-preclinical-data-on-hepatitis-b-therapeutic-vaccine-at-easl-2025 2025-04-25T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearb-therapeutics-to-present-promising-preclinical-data-on-hepatitis-b-therapeutic-vaccine-at-easl-2025 2025-04-25T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-showcases-extensive-clinical-evidence-for-transplant-monitoring-solutions-at-ishlt-2025 2025-04-25T13:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-showcases-extensive-clinical-evidence-for-transplant-monitoring-solutions-at-ishlt-2025 2025-04-25T13:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-reports-strong-2024-financial-results-with-first-commercial-revenues-from-iqirvo-r 2025-04-25T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-reports-strong-2024-financial-results-with-first-commercial-revenues-from-iqirvo-r 2025-04-25T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-appoints-renee-aguiar-lucander-as-new-ceo-marking-new-growth-phase 2025-04-25T10:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-appoints-renee-aguiar-lucander-as-new-ceo-marking-new-growth-phase 2025-04-25T10:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/nordic-pharma-launches-authorized-generic-of-maxitrol-for-bacterial-eye-infections 2025-04-25T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nordic-pharma-launches-authorized-generic-of-maxitrol-for-bacterial-eye-infections 2025-04-25T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/syncromune-to-present-phase-1-data-on-novel-sync-t-therapy-for-metastatic-prostate-cancer-at-asco-2025 2025-04-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syncromune-to-present-phase-1-data-on-novel-sync-t-therapy-for-metastatic-prostate-cancer-at-asco-2025 2025-04-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-circa-scientific-s-pericrosstm-epicardial-access-kit-with-100-success-rate-in-clinical-trial 2025-04-25T04:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-circa-scientific-s-pericrosstm-epicardial-access-kit-with-100-success-rate-in-clinical-trial 2025-04-25T04:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/allarity-therapeutics-unveils-novel-predictive-tool-for-daratumumab-response-in-multiple-myeloma-patients 2025-04-25T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allarity-therapeutics-unveils-novel-predictive-tool-for-daratumumab-response-in-multiple-myeloma-patients 2025-04-25T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-analysis-reveals-20-therapies-in-development-for-open-angle-glaucoma-treatment 2025-04-25T01:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-analysis-reveals-20-therapies-in-development-for-open-angle-glaucoma-treatment 2025-04-25T01:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/avidicure-launches-with-50m-to-develop-novel-multifunctional-antibody-platform-for-cancer 2025-04-25T01:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidicure-launches-with-50m-to-develop-novel-multifunctional-antibody-platform-for-cancer 2025-04-25T01:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-s-bpm31510-demonstrates-breakthrough-blood-brain-barrier-penetration-for-mitochondrial-disease-treatment 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bpgbio-s-bpm31510-demonstrates-breakthrough-blood-brain-barrier-penetration-for-mitochondrial-disease-treatment 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avvio-medical-to-present-novel-urological-device-trial-results-at-2025-aua-annual-meeting 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avvio-medical-to-present-novel-urological-device-trial-results-at-2025-aua-annual-meeting 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cn-bio-and-pharmaron-partner-to-advance-organ-on-a-chip-technology-for-drug-development 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cn-bio-and-pharmaron-partner-to-advance-organ-on-a-chip-technology-for-drug-development 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-therapeutics-completes-13-8-million-public-offering-to-advance-cancer-immunotherapy-pipeline 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briacell-therapeutics-completes-13-8-million-public-offering-to-advance-cancer-immunotherapy-pipeline 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/grove-biopharma-secures-30m-funding-expands-to-new-r-d-facility-in-chicago-s-fulton-market 2025-04-24T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grove-biopharma-secures-30m-funding-expands-to-new-r-d-facility-in-chicago-s-fulton-market 2025-04-24T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-to-reveal-dual-mechanism-of-novel-cyclin-a-b-rxl-inhibitors-at-aacr-2025 2025-04-24T23:36:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circle-pharma-to-reveal-dual-mechanism-of-novel-cyclin-a-b-rxl-inhibitors-at-aacr-2025 2025-04-24T23:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/montana-pioneers-experimental-treatment-hub-with-new-legislation-expanding-right-to-try 2025-04-24T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montana-pioneers-experimental-treatment-hub-with-new-legislation-expanding-right-to-try 2025-04-24T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/lumicera-and-costco-partner-to-expand-cost-plus-specialty-pharmacy-services-for-chronic-and-rare-conditions 2025-04-24T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumicera-and-costco-partner-to-expand-cost-plus-specialty-pharmacy-services-for-chronic-and-rare-conditions 2025-04-24T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/araceli-biosciences-secures-11-2m-seed-funding-to-accelerate-ai-powered-drug-discovery-imaging 2025-04-24T22:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/araceli-biosciences-secures-11-2m-seed-funding-to-accelerate-ai-powered-drug-discovery-imaging 2025-04-24T22:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/corwave-s-novel-lvad-shows-promising-results-in-6-month-preclinical-study-advancing-to-human-trials 2025-04-24T22:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corwave-s-novel-lvad-shows-promising-results-in-6-month-preclinical-study-advancing-to-human-trials 2025-04-24T22:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-launches-4500-crore-qip-to-strengthen-balance-sheet-and-reduce-debt 2025-04-24T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-launches-4500-crore-qip-to-strengthen-balance-sheet-and-reduce-debt 2025-04-24T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-and-pfizer-form-strategic-alliance-to-advance-cancer-therapies-using-liquid-biopsy-technology 2025-04-24T20:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-and-pfizer-form-strategic-alliance-to-advance-cancer-therapies-using-liquid-biopsy-technology 2025-04-24T20:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/topas-therapeutics-to-present-promising-phase-2a-data-for-novel-celiac-disease-treatment-at-ddw-2025 2025-04-24T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topas-therapeutics-to-present-promising-phase-2a-data-for-novel-celiac-disease-treatment-at-ddw-2025 2025-04-24T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/mosaic-therapeutics-acquires-two-clinical-stage-oncology-programs-from-astex-to-develop-novel-combination-therapies 2025-04-24T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosaic-therapeutics-acquires-two-clinical-stage-oncology-programs-from-astex-to-develop-novel-combination-therapies 2025-04-24T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-seeks-fda-approval-for-novel-serotype-e-botulinum-neurotoxin-for-glabellar-lines 2025-04-24T19:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-seeks-fda-approval-for-novel-serotype-e-botulinum-neurotoxin-for-glabellar-lines 2025-04-24T19:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/amplifier-health-and-xeomics-partner-to-advance-voice-based-diagnostic-ai-with-750000-global-voice-samples 2025-04-24T19:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplifier-health-and-xeomics-partner-to-advance-voice-based-diagnostic-ai-with-750000-global-voice-samples 2025-04-24T19:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-s-plozasiran-for-familial-chylomicronemia-syndrome-fast-tracked-for-eu-approval 2025-04-24T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-s-plozasiran-for-familial-chylomicronemia-syndrome-fast-tracked-for-eu-approval 2025-04-24T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-submits-interoperable-insulin-pump-to-fda-advancing-abbott-partnership 2025-04-24T19:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-submits-interoperable-insulin-pump-to-fda-advancing-abbott-partnership 2025-04-24T19:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-halts-balinatunfib-monotherapy-development-after-phase-ii-psoriasis-trial-miss 2025-04-24T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-halts-balinatunfib-monotherapy-development-after-phase-ii-psoriasis-trial-miss 2025-04-24T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarcopenia-pipeline-shows-robust-growth-with-18-pharma-companies-developing-novel-therapies 2025-04-24T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarcopenia-pipeline-shows-robust-growth-with-18-pharma-companies-developing-novel-therapies 2025-04-24T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytoagents-advances-phase-1b-2a-trial-of-cto1681-for-cytokine-release-syndrome-in-car-t-cell-therapy-patients 2025-04-24T17:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytoagents-advances-phase-1b-2a-trial-of-cto1681-for-cytokine-release-syndrome-in-car-t-cell-therapy-patients 2025-04-24T17:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/dt-109-novel-glycine-based-compound-shows-dual-efficacy-against-atherosclerosis-and-mash 2025-04-24T17:33:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dt-109-novel-glycine-based-compound-shows-dual-efficacy-against-atherosclerosis-and-mash 2025-04-24T17:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/promising-alzheimer-s-vaccine-targeting-tau-protein-advances-toward-human-trials 2025-04-24T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-alzheimer-s-vaccine-targeting-tau-protein-advances-toward-human-trials 2025-04-24T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-q3-2025-approval-dates-for-three-breakthrough-therapies-targeting-rare-diseases 2025-04-24T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-q3-2025-approval-dates-for-three-breakthrough-therapies-targeting-rare-diseases 2025-04-24T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/india-conducts-first-human-gene-therapy-trial-for-hemophilia-in-landmark-collaboration 2025-04-24T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-conducts-first-human-gene-therapy-trial-for-hemophilia-in-landmark-collaboration 2025-04-24T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/veraxa-biotech-and-voyager-acquisition-to-merge-creating-1-64b-nasdaq-listed-cancer-therapeutics-company 2025-04-24T16:37:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veraxa-biotech-and-voyager-acquisition-to-merge-creating-1-64b-nasdaq-listed-cancer-therapeutics-company 2025-04-24T16:37:23+00:00 hourly 0.9 https://trial.medpath.com/news/renibus-completes-enrollment-in-pivotal-phase-3-protect-trial-of-rbt-1-for-cardiac-surgery-complications 2025-04-24T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renibus-completes-enrollment-in-pivotal-phase-3-protect-trial-of-rbt-1-for-cardiac-surgery-complications 2025-04-24T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/entod-pharmaceuticals-receives-first-global-approval-for-0-05-atropine-eye-drops-to-combat-childhood-myopia 2025-04-24T16:37:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entod-pharmaceuticals-receives-first-global-approval-for-0-05-atropine-eye-drops-to-combat-childhood-myopia 2025-04-24T16:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/liverpool-researchers-trial-oral-treatment-for-deadly-leishmaniasis-disease 2025-04-24T16:36:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liverpool-researchers-trial-oral-treatment-for-deadly-leishmaniasis-disease 2025-04-24T16:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-s-antiviral-cdi-988-shows-potent-activity-against-emerging-norovirus-variants 2025-04-24T16:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocrystal-pharma-s-antiviral-cdi-988-shows-potent-activity-against-emerging-norovirus-variants 2025-04-24T16:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-launches-magic-i-first-national-genomics-study-to-transform-childhood-cancer-care 2025-04-24T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ireland-launches-magic-i-first-national-genomics-study-to-transform-childhood-cancer-care 2025-04-24T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-to-present-key-hepatitis-b-and-delta-clinical-data-at-easl-congress-2025 2025-04-24T16:35:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-to-present-key-hepatitis-b-and-delta-clinical-data-at-easl-congress-2025 2025-04-24T16:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-advances-dual-breakthrough-programs-in-targeted-protein-degradation-at-aacr-2025 2025-04-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seed-therapeutics-advances-dual-breakthrough-programs-in-targeted-protein-degradation-at-aacr-2025 2025-04-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/akoya-biosciences-launches-advanced-adc-breast-cancer-assay-for-precision-oncology 2025-04-24T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akoya-biosciences-launches-advanced-adc-breast-cancer-assay-for-precision-oncology 2025-04-24T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/granite-bio-emerges-with-100m-funding-and-novel-immunology-pipeline-for-ibd-and-allergies 2025-04-24T16:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granite-bio-emerges-with-100m-funding-and-novel-immunology-pipeline-for-ibd-and-allergies 2025-04-24T16:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ferring-pharmaceuticals-new-manufacturing-facility-for-bladder-cancer-gene-therapy-adstiladrin 2025-04-24T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ferring-pharmaceuticals-new-manufacturing-facility-for-bladder-cancer-gene-therapy-adstiladrin 2025-04-24T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/inhalerx-secures-38-5-million-funding-to-advance-novel-inhaled-therapies-for-cancer-pain-and-panic-disorder 2025-04-24T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhalerx-secures-38-5-million-funding-to-advance-novel-inhaled-therapies-for-cancer-pain-and-panic-disorder 2025-04-24T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-hormonal-male-contraceptive-adam-shows-two-year-efficacy-in-clinical-trials 2025-04-24T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-non-hormonal-male-contraceptive-adam-shows-two-year-efficacy-in-clinical-trials 2025-04-24T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/koelis-and-bot-image-partner-to-enhance-prostate-cancer-detection-with-ai-powered-fusion-biopsy-technology 2025-04-24T16:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/koelis-and-bot-image-partner-to-enhance-prostate-cancer-detection-with-ai-powered-fusion-biopsy-technology 2025-04-24T16:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/cell-therapy-advances-show-promise-for-hepatocellular-carcinoma-treatment 2025-04-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-therapy-advances-show-promise-for-hepatocellular-carcinoma-treatment 2025-04-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/varenicline-shows-promising-results-for-youth-vaping-cessation-in-landmark-trial 2025-04-24T14:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varenicline-shows-promising-results-for-youth-vaping-cessation-in-landmark-trial 2025-04-24T14:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-04-24T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-s-farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-04-24T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-baloxavir-significantly-reduces-household-influenza-transmission-in-global-phase-iii-trial 2025-04-24T13:36:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-baloxavir-significantly-reduces-household-influenza-transmission-in-global-phase-iii-trial 2025-04-24T13:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/promising-pipeline-for-mantle-cell-lymphoma-treatment-22-therapies-under-development-by-20-companies 2025-04-24T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-pipeline-for-mantle-cell-lymphoma-treatment-22-therapies-under-development-by-20-companies 2025-04-24T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/etiome-emerges-with-50m-to-target-disease-biomarkers-before-symptoms-appear 2025-04-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/etiome-emerges-with-50m-to-target-disease-biomarkers-before-symptoms-appear 2025-04-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/summit-s-ivonescimab-shows-promise-in-phase-iii-trial-against-established-lung-cancer-therapies 2025-04-24T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-s-ivonescimab-shows-promise-in-phase-iii-trial-against-established-lung-cancer-therapies 2025-04-24T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/medit-and-graphy-form-strategic-alliance-to-transform-digital-orthodontics-with-3d-printed-clear-aligners 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medit-and-graphy-form-strategic-alliance-to-transform-digital-orthodontics-with-3d-printed-clear-aligners 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-s-multi-antigen-covid-19-vaccine-shows-promising-results-in-immunocompromised-patients 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-s-multi-antigen-covid-19-vaccine-shows-promising-results-in-immunocompromised-patients 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/hydrogel-coated-membranes-reduce-t-cell-exhaustion-in-car-t-manufacturing 2025-04-24T11:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydrogel-coated-membranes-reduce-t-cell-exhaustion-in-car-t-manufacturing 2025-04-24T11:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-elafibranor-shows-promise-in-phase-ii-trial-for-primary-sclerosing-cholangitis 2025-04-24T10:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-elafibranor-shows-promise-in-phase-ii-trial-for-primary-sclerosing-cholangitis 2025-04-24T10:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/cytovation-secures-6m-funding-to-advance-cy-101-cancer-therapy-into-phase-ii-trials 2025-04-24T10:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytovation-secures-6m-funding-to-advance-cy-101-cancer-therapy-into-phase-ii-trials 2025-04-24T10:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-and-moebius-medical-s-mm-ii-shows-promising-results-for-knee-osteoarthritis-in-phase-2b-trial 2025-04-24T10:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-and-moebius-medical-s-mm-ii-shows-promising-results-for-knee-osteoarthritis-in-phase-2b-trial 2025-04-24T10:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/lotte-biologics-launches-dedicated-adc-manufacturing-facility-with-first-client-contract 2025-04-24T10:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lotte-biologics-launches-dedicated-adc-manufacturing-facility-with-first-client-contract 2025-04-24T10:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-and-oncodesign-services-partner-to-advance-radiopharmaceutical-research-with-abylinktm-technology 2025-04-24T10:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debiopharm-and-oncodesign-services-partner-to-advance-radiopharmaceutical-research-with-abylinktm-technology 2025-04-24T10:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/turbine-unveils-first-ever-virtual-lab-platform-for-cell-simulations-in-drug-development 2025-04-24T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turbine-unveils-first-ever-virtual-lab-platform-for-cell-simulations-in-drug-development 2025-04-24T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/archetype-therapeutics-to-present-ai-discovered-lung-cancer-drug-candidates-at-aacr-2025 2025-04-24T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archetype-therapeutics-to-present-ai-discovered-lung-cancer-drug-candidates-at-aacr-2025 2025-04-24T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/antengene-to-showcase-six-innovative-cancer-therapies-at-aacr-and-asco-2025 2025-04-24T07:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antengene-to-showcase-six-innovative-cancer-therapies-at-aacr-and-asco-2025 2025-04-24T07:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/selution-slr-drug-eluting-balloon-shows-exceptional-3-year-patency-rates-in-peripheral-artery-disease-trials 2025-04-24T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selution-slr-drug-eluting-balloon-shows-exceptional-3-year-patency-rates-in-peripheral-artery-disease-trials 2025-04-24T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/sagemedic-s-3d-microtumor-assay-shows-promise-for-personalized-cancer-treatment-at-aacr-2025 2025-04-24T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagemedic-s-3d-microtumor-assay-shows-promise-for-personalized-cancer-treatment-at-aacr-2025 2025-04-24T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharma-to-present-positive-phase-2-data-for-tirabrutinib-in-pcnsl-and-ono-4578-in-rectal-cancer-at-asco-2025 2025-04-24T04:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharma-to-present-positive-phase-2-data-for-tirabrutinib-in-pcnsl-and-ono-4578-in-rectal-cancer-at-asco-2025 2025-04-24T04:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitor-selection-in-myelofibrosis-balancing-anemia-management-with-disease-control 2025-04-24T03:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitor-selection-in-myelofibrosis-balancing-anemia-management-with-disease-control 2025-04-24T03:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-battles-fda-over-gastroparesis-drug-hearing-delays 2025-04-24T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-battles-fda-over-gastroparesis-drug-hearing-delays 2025-04-24T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/orphan-therapeutics-accelerator-pioneers-novel-funding-model-to-rescue-ultra-rare-disease-treatments 2025-04-24T02:03:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphan-therapeutics-accelerator-pioneers-novel-funding-model-to-rescue-ultra-rare-disease-treatments 2025-04-24T02:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-biologics-to-present-breakthrough-clinical-data-for-ibi363-pd-1-il-2-bispecific-antibody-at-asco-2025 2025-04-24T01:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-biologics-to-present-breakthrough-clinical-data-for-ibi363-pd-1-il-2-bispecific-antibody-at-asco-2025 2025-04-24T01:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/grail-to-present-real-world-data-from-100000-galleri-multi-cancer-detection-tests-at-aacr-2025 2025-04-24T01:36:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grail-to-present-real-world-data-from-100000-galleri-multi-cancer-detection-tests-at-aacr-2025 2025-04-24T01:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-increased-kidney-and-liver-toxicity-with-pembrolizumab-chemotherapy-combination-in-lung-cancer 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-increased-kidney-and-liver-toxicity-with-pembrolizumab-chemotherapy-combination-in-lung-cancer 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/itm-and-alpha-9-oncology-partner-to-supply-rare-actinium-225-for-advanced-cancer-therapies 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-and-alpha-9-oncology-partner-to-supply-rare-actinium-225-for-advanced-cancer-therapies 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-delgocitinib-cream-outperforms-alitretinoin-in-landmark-delta-force-trial-for-chronic-hand-eczema 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-s-delgocitinib-cream-outperforms-alitretinoin-in-landmark-delta-force-trial-for-chronic-hand-eczema 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytics-biotech-to-present-pelareorep-data-for-pancreatic-cancer-at-asco-2025 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytics-biotech-to-present-pelareorep-data-for-pancreatic-cancer-at-asco-2025 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-secures-90-million-in-public-offering-to-advance-rare-disease-therapies 2025-04-23T23:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-secures-90-million-in-public-offering-to-advance-rare-disease-therapies 2025-04-23T23:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-of-transform-trial-shows-sustained-benefits-of-liso-cel-car-t-cell-therapy-in-relapsed-lbcl 2025-04-23T22:37:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-follow-up-of-transform-trial-shows-sustained-benefits-of-liso-cel-car-t-cell-therapy-in-relapsed-lbcl 2025-04-23T22:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/sickle-cell-disease-pipeline-shows-robust-growth-with-60-therapies-in-development-across-multiple-clinical-phases 2025-04-23T22:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sickle-cell-disease-pipeline-shows-robust-growth-with-60-therapies-in-development-across-multiple-clinical-phases 2025-04-23T22:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/sakar-healthcare-secures-second-eu-marketing-authorization-for-colorectal-cancer-treatment 2025-04-23T22:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sakar-healthcare-secures-second-eu-marketing-authorization-for-colorectal-cancer-treatment 2025-04-23T22:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-to-showcase-breakthrough-cancer-therapies-at-asco-2025-with-over-60-presentations 2025-04-23T22:36:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-to-showcase-breakthrough-cancer-therapies-at-asco-2025-with-over-60-presentations 2025-04-23T22:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-warns-of-serious-side-effects-from-unapproved-topical-finasteride-hair-loss-treatments 2025-04-23T22:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-warns-of-serious-side-effects-from-unapproved-topical-finasteride-hair-loss-treatments 2025-04-23T22:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-tempus-ai-forge-200-million-oncology-ai-partnership-to-accelerate-cancer-drug-discovery 2025-04-23T20:36:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-tempus-ai-forge-200-million-oncology-ai-partnership-to-accelerate-cancer-drug-discovery 2025-04-23T20:36:57+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-cystic-fibrosis-drug-alyftrek-receives-chmp-recommendation-for-eu-approval 2025-04-23T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-s-cystic-fibrosis-drug-alyftrek-receives-chmp-recommendation-for-eu-approval 2025-04-23T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-ab8939-for-acute-myeloid-leukemia-treatment 2025-04-23T19:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-ab8939-for-acute-myeloid-leukemia-treatment 2025-04-23T19:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-fermentalg-and-givaudan-s-acid-stable-natural-blue-food-colorant 2025-04-23T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-fermentalg-and-givaudan-s-acid-stable-natural-blue-food-colorant 2025-04-23T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/chimeric-therapeutics-raises-6-6-million-to-advance-novel-car-t-and-nk-cell-cancer-therapies 2025-04-23T19:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chimeric-therapeutics-raises-6-6-million-to-advance-novel-car-t-and-nk-cell-cancer-therapies 2025-04-23T19:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/nanostics-begins-clinical-utility-study-for-ai-powered-prostate-cancer-test 2025-04-23T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanostics-begins-clinical-utility-study-for-ai-powered-prostate-cancer-test 2025-04-23T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/biopoly-begins-fda-approved-clinical-trial-for-novel-knee-cartilage-implant 2025-04-23T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopoly-begins-fda-approved-clinical-trial-for-novel-knee-cartilage-implant 2025-04-23T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-reveals-how-vagus-nerve-encodes-immune-signals-during-inflammation 2025-04-23T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-research-reveals-how-vagus-nerve-encodes-immune-signals-during-inflammation 2025-04-23T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-apremilast-shows-dual-potential-for-alcohol-use-disorder-and-pain-management 2025-04-23T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-apremilast-shows-dual-potential-for-alcohol-use-disorder-and-pain-management 2025-04-23T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-reports-positive-phase-3-results-for-ivonescimab-in-lung-cancer-building-on-recent-fda-approval-success 2025-04-23T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-reports-positive-phase-3-results-for-ivonescimab-in-lung-cancer-building-on-recent-fda-approval-success 2025-04-23T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-astrazeneca-and-pathos-ai-form-200m-collaboration-to-build-oncology-foundation-model 2025-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-astrazeneca-and-pathos-ai-form-200m-collaboration-to-build-oncology-foundation-model 2025-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-secures-landmark-victory-against-moderna-in-korean-mrna-patent-dispute 2025-04-23T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-secures-landmark-victory-against-moderna-in-korean-mrna-patent-dispute 2025-04-23T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/baebies-secures-fda-breakthrough-designation-for-first-point-of-care-heparin-monitoring-test 2025-04-23T16:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baebies-secures-fda-breakthrough-designation-for-first-point-of-care-heparin-monitoring-test 2025-04-23T16:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/trustpoint-and-hexagon-secure-1-2m-navair-contract-to-develop-revolutionary-c-band-gnss-technology 2025-04-23T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trustpoint-and-hexagon-secure-1-2m-navair-contract-to-develop-revolutionary-c-band-gnss-technology 2025-04-23T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-t1d-invests-2-8-million-to-establish-joint-cardiorenal-center-of-excellence-for-type-1-diabetes-research 2025-04-23T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-t1d-invests-2-8-million-to-establish-joint-cardiorenal-center-of-excellence-for-type-1-diabetes-research 2025-04-23T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-s-plasma-proteomics-research-reveals-key-mechanisms-of-immunotherapy-resistance-in-nsclc 2025-04-23T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-s-plasma-proteomics-research-reveals-key-mechanisms-of-immunotherapy-resistance-in-nsclc 2025-04-23T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-patent-for-novel-methadone-based-opioid-use-disorder-treatment 2025-04-23T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-secures-patent-for-novel-methadone-based-opioid-use-disorder-treatment 2025-04-23T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/cerevasc-s-eshunt-system-receives-fda-breakthrough-designation-for-pediatric-hydrocephalus-treatment 2025-04-23T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerevasc-s-eshunt-system-receives-fda-breakthrough-designation-for-pediatric-hydrocephalus-treatment 2025-04-23T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprazan-outperforms-standard-ppi-therapy-in-phase-3-gerd-trials 2025-04-23T16:36:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tegoprazan-outperforms-standard-ppi-therapy-in-phase-3-gerd-trials 2025-04-23T16:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-and-tessellate-bio-form-eur500m-partnership-to-target-alt-positive-cancers 2025-04-23T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-and-tessellate-bio-form-eur500m-partnership-to-target-alt-positive-cancers 2025-04-23T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-phase-3-panova-3-trial-shows-promising-results-for-pancreatic-cancer-treatment 2025-04-23T16:36:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-s-phase-3-panova-3-trial-shows-promising-results-for-pancreatic-cancer-treatment 2025-04-23T16:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/peanut-allergy-treatment-market-poised-for-16-growth-as-new-therapies-enter-pipeline 2025-04-23T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peanut-allergy-treatment-market-poised-for-16-growth-as-new-therapies-enter-pipeline 2025-04-23T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-mursla-bio-s-evoliver-test-for-early-liver-cancer-detection 2025-04-23T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-mursla-bio-s-evoliver-test-for-early-liver-cancer-detection 2025-04-23T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-unveils-advanced-cancer-genomic-profiling-tools-at-aacr-2025 2025-04-23T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-unveils-advanced-cancer-genomic-profiling-tools-at-aacr-2025 2025-04-23T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/lakeshore-biopharma-launches-first-needle-free-rabies-vaccine-reconstitution-system-in-china 2025-04-23T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lakeshore-biopharma-launches-first-needle-free-rabies-vaccine-reconstitution-system-in-china 2025-04-23T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-partners-with-repertoire-immune-medicines-in-765m-deal-for-autoimmune-disease-drug-discovery 2025-04-23T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-partners-with-repertoire-immune-medicines-in-765m-deal-for-autoimmune-disease-drug-discovery 2025-04-23T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-appoints-utpal-singh-as-cso-to-advance-peptide-therapeutics-for-obesity 2025-04-23T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-appoints-utpal-singh-as-cso-to-advance-peptide-therapeutics-for-obesity 2025-04-23T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/sylvester-comprehensive-cancer-center-to-present-groundbreaking-research-at-asco-2025-annual-meeting 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sylvester-comprehensive-cancer-center-to-present-groundbreaking-research-at-asco-2025-annual-meeting 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiff-oncology-secures-second-patent-for-onvansertib-in-bevacizumab-naive-mcrc-patients 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiff-oncology-secures-second-patent-for-onvansertib-in-bevacizumab-naive-mcrc-patients 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/merus-to-present-petosemtamab-combination-therapy-data-for-head-and-neck-cancer-at-2025-asco-meeting 2025-04-23T15:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merus-to-present-petosemtamab-combination-therapy-data-for-head-and-neck-cancer-at-2025-asco-meeting 2025-04-23T15:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/hawaii-advances-psychedelic-assisted-therapy-research-bill-with-4-million-funding-potential 2025-04-23T15:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hawaii-advances-psychedelic-assisted-therapy-research-bill-with-4-million-funding-potential 2025-04-23T15:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-promise-for-slowing-biological-aging-and-improving-cognition-in-hiv-patients 2025-04-23T14:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-shows-promise-for-slowing-biological-aging-and-improving-cognition-in-hiv-patients 2025-04-23T14:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/cuban-drug-jusvinza-advances-through-phase-iii-trial-for-rheumatoid-arthritis-treatment 2025-04-23T11:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuban-drug-jusvinza-advances-through-phase-iii-trial-for-rheumatoid-arthritis-treatment 2025-04-23T11:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/remap-cap-trial-shows-hydrocortisone-reduces-mortality-in-severe-community-acquired-pneumonia 2025-04-23T11:00:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remap-cap-trial-shows-hydrocortisone-reduces-mortality-in-severe-community-acquired-pneumonia 2025-04-23T11:00:14+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-reverses-course-on-company-split-appoints-henry-gosebruch-as-new-ceo 2025-04-23T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-reverses-course-on-company-split-appoints-henry-gosebruch-as-new-ceo 2025-04-23T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-demonstrates-first-ever-degradation-of-erg-in-prostate-cancer-models 2025-04-23T09:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parabilis-medicines-demonstrates-first-ever-degradation-of-erg-in-prostate-cancer-models 2025-04-23T09:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-da-1241-shows-enhanced-hepatoprotective-effects-in-mash-combination-therapy 2025-04-23T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metavia-s-da-1241-shows-enhanced-hepatoprotective-effects-in-mash-combination-therapy 2025-04-23T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/calidi-biotherapeutics-appoints-eric-poma-as-new-ceo-to-advance-novel-cancer-virotherapy-platform 2025-04-23T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calidi-biotherapeutics-appoints-eric-poma-as-new-ceo-to-advance-novel-cancer-virotherapy-platform 2025-04-23T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-to-present-phase-1-data-on-novel-dll3-targeted-adc-for-small-cell-lung-cancer-at-asco-2025 2025-04-23T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-to-present-phase-1-data-on-novel-dll3-targeted-adc-for-small-cell-lung-cancer-at-asco-2025 2025-04-23T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/obi-pharma-s-novel-trop2-adc-obi-902-receives-fda-ind-clearance-for-phase-1-2-trial-using-proprietary-glycobi-r-technology 2025-04-23T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obi-pharma-s-novel-trop2-adc-obi-902-receives-fda-ind-clearance-for-phase-1-2-trial-using-proprietary-glycobi-r-technology 2025-04-23T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-avava-s-focal-point-technology-for-acne-scar-treatment-across-all-skin-types 2025-04-23T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-avava-s-focal-point-technology-for-acne-scar-treatment-across-all-skin-types 2025-04-23T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/novita-s-fascin-inhibitor-np-g2-044-shows-promising-results-in-phase-2-trial-for-advanced-solid-tumors 2025-04-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novita-s-fascin-inhibitor-np-g2-044-shows-promising-results-in-phase-2-trial-for-advanced-solid-tumors 2025-04-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mallinckrodt-to-present-five-clinical-studies-on-terlivaz-for-hepatorenal-syndrome-at-ddw-2025 2025-04-23T06:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mallinckrodt-to-present-five-clinical-studies-on-terlivaz-for-hepatorenal-syndrome-at-ddw-2025 2025-04-23T06:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/abtherx-partners-with-rondo-and-spice-biotechnologies-to-accelerate-bispecific-antibody-development-for-cancer-immunotherapy 2025-04-23T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abtherx-partners-with-rondo-and-spice-biotechnologies-to-accelerate-bispecific-antibody-development-for-cancer-immunotherapy 2025-04-23T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-partners-with-davos-alzheimer-s-collaborative-on-groundbreaking-north-african-dementia-registry 2025-04-23T05:18:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacbio-partners-with-davos-alzheimer-s-collaborative-on-groundbreaking-north-african-dementia-registry 2025-04-23T05:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/genscript-biotech-and-nsg-bio-form-strategic-partnership-to-accelerate-biotech-innovation-in-singapore 2025-04-23T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genscript-biotech-and-nsg-bio-form-strategic-partnership-to-accelerate-biotech-innovation-in-singapore 2025-04-23T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-monitoring-shows-promise-for-predicting-melanoma-recurrence-after-surgery 2025-04-23T02:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-monitoring-shows-promise-for-predicting-melanoma-recurrence-after-surgery 2025-04-23T02:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-biopharma-to-present-promising-imdusiran-and-ab-101-data-for-chronic-hepatitis-b-at-easl-congress-2025 2025-04-23T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arbutus-biopharma-to-present-promising-imdusiran-and-ab-101-data-for-chronic-hepatitis-b-at-easl-congress-2025 2025-04-23T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-partners-with-concertai-to-accelerate-precision-oncology-drug-development-using-ai 2025-04-23T02:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-partners-with-concertai-to-accelerate-precision-oncology-drug-development-using-ai 2025-04-23T02:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-rec-4881-shows-30-polyp-reduction-in-fap-patients-in-phase-1b-2-trial 2025-04-23T01:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-s-rec-4881-shows-30-polyp-reduction-in-fap-patients-in-phase-1b-2-trial 2025-04-23T01:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-pharmaceuticals-hypochlorous-acid-based-acne-products-gain-uk-regulatory-approval 2025-04-23T01:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoma-pharmaceuticals-hypochlorous-acid-based-acne-products-gain-uk-regulatory-approval 2025-04-23T01:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-showcases-efanesoctocog-alfa-data-from-xtend-phase-3-program-at-wfh-2025-summit 2025-04-23T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-showcases-efanesoctocog-alfa-data-from-xtend-phase-3-program-at-wfh-2025-summit 2025-04-23T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-pfizer-lyme-disease-vaccine-shows-promise-with-strong-booster-response-in-phase-2-trial 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-pfizer-lyme-disease-vaccine-shows-promise-with-strong-booster-response-in-phase-2-trial 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-olumiant-shows-promise-in-preserving-beta-cell-function-in-type-1-diabetes 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-olumiant-shows-promise-in-preserving-beta-cell-function-in-type-1-diabetes 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/migraine-treatment-pipeline-shows-robust-activity-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/migraine-treatment-pipeline-shows-robust-activity-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cell-ai-launches-oncoincytes-revolutionary-multi-modal-cancer-diagnostic-panel-for-precision-oncology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1cell-ai-launches-oncoincytes-revolutionary-multi-modal-cancer-diagnostic-panel-for-precision-oncology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-receives-u-s-patent-for-hybrid-voice-and-gesture-control-technology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-devices-receives-u-s-patent-for-hybrid-voice-and-gesture-control-technology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-and-element-biosciences-form-strategic-alliance-to-expand-ngs-technology-access-across-global-markets 2025-04-22T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-solutions-and-element-biosciences-form-strategic-alliance-to-expand-ngs-technology-access-across-global-markets 2025-04-22T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-ceo-paul-stoffels-to-step-down-as-company-splits-into-two-entities 2025-04-22T23:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-ceo-paul-stoffels-to-step-down-as-company-splits-into-two-entities 2025-04-22T23:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-cobenfy-fails-to-meet-primary-endpoint-as-adjunctive-schizophrenia-treatment-in-phase-3-arise-trial 2025-04-22T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-cobenfy-fails-to-meet-primary-endpoint-as-adjunctive-schizophrenia-treatment-in-phase-3-arise-trial 2025-04-22T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/novonesis-invests-5-million-to-expand-biotechnology-operations-in-salem-virginia 2025-04-22T22:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novonesis-invests-5-million-to-expand-biotechnology-operations-in-salem-virginia 2025-04-22T22:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-ogsiveo-expected-to-receive-positive-chmp-opinion-boosting-european-market-potential 2025-04-22T19:36:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springworks-ogsiveo-expected-to-receive-positive-chmp-opinion-boosting-european-market-potential 2025-04-22T19:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ark-surgical-s-lapbox-power-first-dual-wall-system-for-both-manual-and-power-morcellation 2025-04-22T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ark-surgical-s-lapbox-power-first-dual-wall-system-for-both-manual-and-power-morcellation 2025-04-22T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/metro-international-biotech-initiates-phase-1a-trial-of-novel-nad-booster-mib-725-for-age-related-diseases 2025-04-22T19:36:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metro-international-biotech-initiates-phase-1a-trial-of-novel-nad-booster-mib-725-for-age-related-diseases 2025-04-22T19:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/elite-clinical-network-and-healthyu-clinics-form-strategic-partnership-to-transform-clinical-research-access 2025-04-22T19:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elite-clinical-network-and-healthyu-clinics-form-strategic-partnership-to-transform-clinical-research-access 2025-04-22T19:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/axoft-s-ultrasoft-brain-computer-interface-shows-promising-results-in-first-human-trial 2025-04-22T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axoft-s-ultrasoft-brain-computer-interface-shows-promising-results-in-first-human-trial 2025-04-22T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-appoints-dr-eyal-attar-as-chief-medical-officer-to-advance-novel-riptac-cancer-platform 2025-04-22T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halda-therapeutics-appoints-dr-eyal-attar-as-chief-medical-officer-to-advance-novel-riptac-cancer-platform 2025-04-22T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/smsbiotech-partners-with-u-s-army-to-develop-stem-cell-therapy-for-chemical-warfare-injuries 2025-04-22T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smsbiotech-partners-with-u-s-army-to-develop-stem-cell-therapy-for-chemical-warfare-injuries 2025-04-22T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-luminopia-s-digital-therapeutic-approval-for-amblyopia-treatment-to-children-aged-8-12 2025-04-22T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-luminopia-s-digital-therapeutic-approval-for-amblyopia-treatment-to-children-aged-8-12 2025-04-22T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/biostate-ai-and-weill-cornell-medicine-partner-to-develop-ai-driven-personalized-treatment-models-for-leukemia 2025-04-22T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostate-ai-and-weill-cornell-medicine-partner-to-develop-ai-driven-personalized-treatment-models-for-leukemia 2025-04-22T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-equally-effective-in-older-and-younger-cancer-patients-despite-immune-phenotype-differences 2025-04-22T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-checkpoint-inhibitors-equally-effective-in-older-and-younger-cancer-patients-despite-immune-phenotype-differences 2025-04-22T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-antibody-drug-conjugate-tgw101-for-advanced-solid-tumor-clinical-trial 2025-04-22T16:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-in-class-antibody-drug-conjugate-tgw101-for-advanced-solid-tumor-clinical-trial 2025-04-22T16:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/sirona-biochem-forms-strategic-partnership-with-promura-gmbh-secures-3m-investment-for-anti-aging-product-development 2025-04-22T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirona-biochem-forms-strategic-partnership-with-promura-gmbh-secures-3m-investment-for-anti-aging-product-development 2025-04-22T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/eu-biosimilar-filings-opinions-and-approvals 2025-04-22T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-biosimilar-filings-opinions-and-approvals 2025-04-22T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/ocumetics-advances-revolutionary-accommodating-intraocular-lens-to-first-in-human-surgery-this-summer 2025-04-22T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocumetics-advances-revolutionary-accommodating-intraocular-lens-to-first-in-human-surgery-this-summer 2025-04-22T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-considers-international-reference-pricing-to-slash-u-s-drug-costs 2025-04-22T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-considers-international-reference-pricing-to-slash-u-s-drug-costs 2025-04-22T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/perfuze-completes-enrollment-in-pivotal-stroke-treatment-trial-strengthens-leadership-team 2025-04-22T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perfuze-completes-enrollment-in-pivotal-stroke-treatment-trial-strengthens-leadership-team 2025-04-22T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/roche-and-regeneron-announce-multi-billion-dollar-investments-in-us-manufacturing-amid-tariff-concerns 2025-04-22T16:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-and-regeneron-announce-multi-billion-dollar-investments-in-us-manufacturing-amid-tariff-concerns 2025-04-22T16:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-licenses-first-in-class-antibody-targeting-activin-e-for-obesity-and-cardiometabolic-diseases 2025-04-22T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-licenses-first-in-class-antibody-targeting-activin-e-for-obesity-and-cardiometabolic-diseases 2025-04-22T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-brainchild-bio-s-car-t-cell-therapy-for-fatal-pediatric-brain-tumors 2025-04-22T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-brainchild-bio-s-car-t-cell-therapy-for-fatal-pediatric-brain-tumors 2025-04-22T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-orchestra-biomed-s-avim-therapy-for-hypertension 2025-04-22T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-orchestra-biomed-s-avim-therapy-for-hypertension 2025-04-22T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-biologic-manufacturing-capacity-with-3-billion-fujifilm-partnership 2025-04-22T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-expands-biologic-manufacturing-capacity-with-3-billion-fujifilm-partnership 2025-04-22T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/malaysia-strengthens-clinical-research-infrastructure-through-strategic-partnerships-and-record-breaking-trial-activity 2025-04-22T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaysia-strengthens-clinical-research-infrastructure-through-strategic-partnerships-and-record-breaking-trial-activity 2025-04-22T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/carthera-enrolls-100-patients-in-landmark-sonobird-trial-using-ultrasound-to-breach-blood-brain-barrier-in-glioblastoma 2025-04-22T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carthera-enrolls-100-patients-in-landmark-sonobird-trial-using-ultrasound-to-breach-blood-brain-barrier-in-glioblastoma 2025-04-22T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/neurovation-labs-secures-patent-for-novel-ptsd-biomarker-detection-technology 2025-04-22T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurovation-labs-secures-patent-for-novel-ptsd-biomarker-detection-technology 2025-04-22T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-microglia-a-revolutionary-approach-to-treating-alzheimer-s-disease 2025-04-22T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-microglia-a-revolutionary-approach-to-treating-alzheimer-s-disease 2025-04-22T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/design-therapeutics-to-present-phase-1-data-for-novel-fecd-eye-drop-treatment-at-ophthalmology-conference 2025-04-22T11:03:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/design-therapeutics-to-present-phase-1-data-for-novel-fecd-eye-drop-treatment-at-ophthalmology-conference 2025-04-22T11:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/cellenkos-novel-off-the-shelf-treg-cell-therapy-demonstrates-promising-results-in-als-clinical-study 2025-04-22T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellenkos-novel-off-the-shelf-treg-cell-therapy-demonstrates-promising-results-in-als-clinical-study 2025-04-22T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipum-s-sol-116-shows-promising-phase-i-results-for-rheumatoid-arthritis-treatment 2025-04-22T10:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipum-s-sol-116-shows-promising-phase-i-results-for-rheumatoid-arthritis-treatment 2025-04-22T10:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/invivoscribe-s-labpmm-secures-new-york-state-approval-for-ultra-sensitive-flt3-itd-mrd-assay-in-aml 2025-04-22T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivoscribe-s-labpmm-secures-new-york-state-approval-for-ultra-sensitive-flt3-itd-mrd-assay-in-aml 2025-04-22T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/1stbio-and-ligachembio-form-strategic-alliance-to-develop-next-generation-oncology-therapeutics 2025-04-22T10:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1stbio-and-ligachembio-form-strategic-alliance-to-develop-next-generation-oncology-therapeutics 2025-04-22T10:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/enhertu-demonstrates-progression-free-survival-benefits-in-advanced-breast-cancer-trial 2025-04-22T10:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhertu-demonstrates-progression-free-survival-benefits-in-advanced-breast-cancer-trial 2025-04-22T10:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/vivasure-medical-secures-ce-mark-for-first-fully-absorbable-large-bore-vascular-closure-system 2025-04-22T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivasure-medical-secures-ce-mark-for-first-fully-absorbable-large-bore-vascular-closure-system 2025-04-22T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-s-shield-multi-cancer-detection-test-shows-strong-performance-across-10-cancer-types 2025-04-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-s-shield-multi-cancer-detection-test-shows-strong-performance-across-10-cancer-types 2025-04-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ensem-therapeutics-ind-for-novel-pi3ka-inhibitor-etx-636-for-advanced-cancer-treatment 2025-04-22T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ensem-therapeutics-ind-for-novel-pi3ka-inhibitor-etx-636-for-advanced-cancer-treatment 2025-04-22T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-to-present-promising-preclinical-data-on-protac-bcl6-degrader-arv-393-at-aacr-2025 2025-04-22T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arvinas-to-present-promising-preclinical-data-on-protac-bcl6-degrader-arv-393-at-aacr-2025 2025-04-22T07:33:51+00:00 hourly 0.9